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The gut microbiota consists of over 1014 commensal bacteria required for proper gut immunity 
development. Commensals also augment the host’s ability to extract energy from the diet. 
Although restricted to the gut lumen by intestinal barrier epithelia, commensals shed microbial 
associated molecule patterns (MAMPs) into the circulation where they augment aspects of 
systemic immunity. Commensals also release fermentation byproducts into the portal blood 
stream. Since the liver receives 80% of its blood via the portal vein and contains a unique 
repertoire of immune cells particularly enriched in Kupffer Cells (KC) and Natural Killer T 
cells, we proposed that gut-derived MAMPs contribute to the development of residential hepatic 
leukocyte subsets. Because of the contributions of gut bacteria to digestion, we suspected that gut 
bacteria add an additional level of regulation to host metabolism and would generate a specific 
hepatic metabolic gene profile. 
Results showed that a cocktail of MAMPs translocate into the portal circulation of 
normal conventional (CL) mice stimulating KC expansion. ICAM1 expression, thought to be 
constitutive on sinusoidal endothelium, was significantly reduced without gut bacteria and was 
required for KC accumulation. The finding that constitutive ICAM1 expression by LSEC was 
dependent on gut bacteria lead us to investigate if the frequency of intra-hepatic lymphocytes 
known to bind ICAM1 were affected by gut bacteria. Results showed that intra-hepatic T 
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lymphocyte populations including NKT (TCRβ+NK1.1+) cells and T helper (CD4+TCRβ+) 
cells were significantly reduced in GF mice and AVMN mice.  
In addition to the significant cellular composition changes of the liver related to gut 
bacteria density, notable changes in murine weight and metabolic gene profiles were observed. 
The average body mass of CL, GF, and AVMN mice was 37.8g, 33.4g, and 34.1g respectively. 
Our whole-liver gene array analysis included 217 probe sets mapped to 163 differentially 
expressed genes between groups, of which forty-eight have roles in lipid metabolism.  
In conclusion, gut bacteria affect both the hepatic metabolic gene profile and the 
inflammatory potential of the liver. These finding have implications for many hepatic 
pathologies including obesity, NAFLD, and autoimmune disease like PBC and AIH mediated by 
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1.0  INTRODUCTION 
The contributions of the gut microbiota to host health and disease are being redefined at an 
alarming pace. The gut microbiota extends its affects to virtually every organ system of the entire 
body (reviewed in (1)), yet the affects of the gut microbiota on the liver have not been 
thoroughly explored with the exception of the endotoxin-related studies primarily carried out in 
vitro. In the subsequent sections, the gut microbiota and liver will be characterized in effort to 
establish the connection(s) between the two regarding liver immunity and metabolism.  
1.1 GUT MICROBIOTA 
1.1.1 Establishment of the Gut Microbiota 
Like all vertebrates, highly complex and genetically diverse communities of microbes inhabit our 
bodies. The gut microbiota, residential microbes of the gastrointestinal tract, exist in largely 
stable but dynamically interactive climax communities (2). However, we are not born bearing 
microbes (3, 4). The complex ecosystem forming the gut microbiota results from the successive 
establishment of bacteria best suited for intestinal niches beginning at birth and extending into 
early childhood (2) (3, 5-9).  
 2 
Bacteria make contact with skin and mucosal surfaces such as the urogenital, respiratory, 
and gastrointestinal tracts (4). Residential gut bacteria (commensals, mutualists, microflora, 
microbiota) are transferred to offspring primarily from their mothers during delivery. Reservoirs 
for human gut bacteria include the maternal fecal flora, maternal skin flora, maternal vaginal 
flora, breast milk, hospital staff, and transmission between infants to name a few (5, 6, 10). Like 
human infants, rodent offspring acquire gut bacteria from their mothers, littermates, and 
environment as well. Our environment serves as a reservoir for aerotolerant bacteria (i.e. 
Enterococci) and bacterial spores (i.e. Clostridium spp.) (5).  
The influences of the intestinal colonization pattern are multi-factorial. Delivery mode 
(vaginal delivery versus Cesarean section), feeding mode (breast milk versus formula), diet, 
family structure (only child versus siblings), course in NICU, hospital hygiene, non-familial care, 
country of residence, age, gender, and host genome (5) (10-12) (13).  Infants delivered by 
Cesarean section were found to have a lower ratio of Anaerobes to Facultatives at one year of 
age suggesting Cesarean section contributes to a lag-time in microbiota maturity (5). Breast milk 
is enriched in many bacteria, specifically Bifidobacteria, which is not typically acquired by 
formula/bottle-fed infants (5). Children without older siblings also exhibit a lower ratio of 
Anaerobes to Facultatives at one year of age (5). Differences in colonization patterns were 
observed in infants of different hospital wards (12). Likewise, differences in colonization 
patterns were noted in mice from different commercial providers and/or housed in different 
rooms of a single animal facility (13). High overlap of gut microbiota between family members 
(most similarity in monozygotic twins) supports host genetics as a contributing factor influencing 
colonization pattern (10, 14).  Diet directly affects gut microbiota development because specific 
bacteria have preferences for particular metabolic substrates (12). While many factors dictating 
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colonization pattern of the gut microbiota are fixed (i.e. genetics), many factors can be exploited 
(i.e. diet) and the capacity to manipulate these factors is evident particularly during the transition 
to a stable microbiota and perturbations thereafter. 
The “Christopher Columbus” colonizers of the gut are heterogeneous and form unstable 
microbial communities distinct from the adult microbiota (15). The first bacterial species to 
arrive to the gut are essentially Facultatives and aerobes including Escherichia coli, Enterococci 
faecalis, and Enterococci faecium (5). Bifidobacterium, Clostridium, and Bacteroides also 
dominate in infants (5). Neonates are rarely colonized by yeast or Lactobacilli (5). Following the 
arrival of Facultatives, which are able to survive in aerated environments, obligate anaerobes 
take foothold concomitant with the transition to weaning (3). As Facultatives expand, they use up 
oxygen thereby creating an increasingly anaerobic environment promoting the expansion of 
anaerobes and the decline of Facultatives (5). Some bacteria are suited to survive the transition 
from milk to solid diet (i.e. Bacteroides thetaiotamicron) while others only appear after the 
introduction of solids (i.e. Peptostreptococci) (5) (10). The introduction of solid food heralds a 
shift in the immature gut microbiota toward the adult microbiota (6). Maturation and stabilization 
of the gut microbiota is a continuous process lasting many years (5). However, 2.5 year-old 
human gut microbiota has nearly the same functional attributes as the human adult microbiota 
(6).  
 The climax communities comprising the adult microbiota of vertebrates are reportedly 
stable and resilient to disruption (2, 6). However, the perturbations imposed by stress, antibiotics, 
prebiotics, and probiotics are unavoidable and their effects are only recently being fully 
understood. Human and rodent exposures to stress lead to compositional alterations in the gut 
microbiota (2). Stress induces neuroendocrine hormones, which increase GI motility and reduces 
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energy substrate availability (2, 12). Antibiotics target members of the gut microbiota, enabling 
other members to expand or new members to become established in the microbial community. 
Changes in gut microbiota composition have been noted with three days of Ciprofloxacin 
administration in humans (11). Many individuals will return to their pre-antibiotic state 
demonstrating only a transient response, but others are unable to return to the community 
structure prior to antibiotic therapy (2, 11). Antibiotic therapy can contribute to permanent long-
term effects on microbiota density and diversity especially with repeated perturbation (11, 16). 
On the other hand, prebiotics (fiber) and probiotics (live non-pathogenic bacteria conferring host 
benefit) typically only have transient affects on the gut microbiota (10, 16). Incorporation of 
probiotic bacteria and/or invasion of pathogen strains of bacteria may be predetermined by what 
phylotypes are already present in an individual (9). At present, the changes in gut bacterial 
density and diversity resulting from perturbation and/or manipulation of the gut microbiota are 
not entirely predictable. 
 
1.1.2 Characteristics of the Gut Microbiota 
The gut microbiota is primarily composed of bacteria (more than 99%), but also consists of small 
numbers viral and fungal members that have not been well characterized to date (4, 8, 15, 17). 
To earn residential status in the gut, autochthonous bacteria must be possess enzymes to harness 
energy from the host diet, be able to evade bacteriophages, resist their host’s immune system, 
and have the ability to proliferate rapidly avoiding washout from peristalsis and bowel 
movements (14). Bacteria in the adult gastrointestinal tract are Facultative anaerobes and strict 
anaerobes. Facultatives can perform aerobic or anaerobic metabolism while strict anaerobes 
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cannot use oxygen because they lack the enzymes to do so (5). Aerotolerant bacteria (i.e. 
Enterococci, Lactobacilli, Enterobacteriaceae family) are predominant in the stomach and small 
intestine and strict anaerobes (i.e. Bacteroides, Bifidobacteria, Clostridium, Fusobacteria, and 
Peptostreptococci) are predominant in the large intestine (5, 18, 19). Anaerobic species (97% of 
microbiota density) reportedly outnumber Facultative species (3% of microbiota density) by a 
factor of one thousand (7, 18). The change in oxygen and availability of substrates allows the 
gastrointestinal tract to support a complex bacterial community with spatial heterogeneity (8, 
18). 
In addition to the longitudinal differences in the microbial communities of the gut 
microbiota, cross sectional differences occur as well. Bacteria with pili and those suited to utilize 
mucus polysaccharides for fuel are more commonly found adherent to the mucosal epithelium 
and within the mucus layer (15). Autochthonous gut bacteria belong to two major bacterial 
divisions, Bacteroidetes and Firmicutes, constituting over 90% of the phylogenetic categories 
characterized in both human and rodent microbiota (10, 14-16, 20), Despite the fact that only two 
of fifty-five known bacterial divisions have been identified within the gut, the microbiota exhibit 
increasing density and diversity in a spatio-temporal manner (Figure 1).      
 
1.1.3 Bacterial Density in the Gut 
The microbiota is estimated to contain 100 trillion (1014) bacteria, the highest of any microbial 
habitat (10, 14, 20). At this density, microbiota members outnumber human cells by a least one 
order of magnitude (2-4, 10, 18). Bacterial density ranges from less than 105/g luminal content in 
the small intestine to up to 1012/g luminal content in the large intestine (2, 19). The acidity of the 
 6 
stomach poses as a bottleneck limiting the numbers of upper gastrointestinal bacterial residents 
(4). The stasis near the ileocecal valve promotes increased bacterial density (5). Lactobacilli, 
despite their notable immunosuppressive affects, are ubiquitous among individuals but only in 
low frequency (2, 5). The genus Bacteroides was found to be the most prevalent, but also the 
most variable among individuals from around the world (15). The most abundant genus in mice 
was Clostridium and Bacteroides was a close second (2). The mucosal immune system keeps 
bacterial density within limits, but perturbations (i.e. antibiotics) result in dysbiosis and changes 
in bacterial abundance.  
Stool and intestinal samples have been utilized to analyze bacterial density and diversity. 
Assessment of bacterial density and diversity was previously quantified and qualified using 
culture based techniques before the 1970’s. The fastidious nutrient requirements and oxygen 
requirements have made it almost prohibitive to use culture techniques to identify the vast 
majority of anaerobes colonizing the gut. DNA based techniques of bacterial detection revealed 
that less than 50% of the microbiota members are cultivatable (5, 18, 19, 21). 16S rRNA gene 
amplification can be used to enumerate bacterial species, while whole gene or partial gene 
sequencing of the variable gene region can be used to assess bacterial diversity (3). However, 
even DNA based techniques are limited by the frequency of bacteria with the microbial 
community found in the gut (5).    
 
1.1.4 Bacterial Diversity in the Gut 
Bacterial diversity in the gastrointestinal tract has received a tremendous deal of attention with 
the Human Microbiome Project (HMP) and The Human Gut Microbiome Initiative (HGMI). 
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Both human and rodents harbor massive numbers of microbes (22). Gut bacteria differ between 
individuals and within individuals spatially descending down the gastrointestinal tract and 
temporally (5, 15). Within gut microbial communities, most taxa change relative to each other on 
a day-to-day basis (11). Interpersonal variation is greater among infants than adults (6) and 
interpersonal variation is less than inter-individual variation (22). Understanding the level of 
complexity and changes in microbiota diversity is confounded by the complexity of sampling, 
DNA processing, and variability in sequencing protocols on one side and the host physiology, 
nutrition, and environment on the other side (15). Still, the human microbiota has an estimated 
one thousand species (4, 7). Qin et al. found that 18 species were common among 124 
individuals, 57 species were common in 90% of the same individuals, and 75 species were 
common among 50% of the same individuals (20). Manichanh et al. demonstrated that the rat 
microbiota possessed more species diversity than human samples (in comparison to two 
sequenced female microbiomes) (16). Mice have more variable diversity, but some species have 
been documented to possess between 30 and 500 species, which overlap with the human 
microbiota (2, 9). 
The concept of a “core” gut microbiome defined by a conserved consortium of species or 
bacterial gene pool shared among individuals has been proposed. A core microbiome could 
ensure conservation of metabolic function performed by gut bacteria (9). However, despite 
functional redundancy among gut bacteria, a single bacterial phylotype was not detectable 
among 154 individuals examined in the study performed by Turbaugh et al. (22). Arumugam et 
al. characterized the microbiota of 22 individuals and categorized individuals with “enterotypes” 
based on the predominant genera (Bacteroides, Prevotella, Rumminococcus), which functionally 
differ in carbohydrate consumption (15). In the future, the “core” gut microbiome will have to be 
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further defined in the face of extensive bacterial diversity influenced by endogenous and 
exogenous factors. Whether or not a functional or phylogenetic “core” microbiome exists, 
bacterial diversity or lack thereof may become a prognostic factor many diseases. Blunted 
microbiota diversity with reduced levels of Bacteroidetes has been identified in both obese mice 
and humans (10, 14). In addition, both Crohn’s Disease and Ulcerative Colitis are associated 
with reduced microbial diversity in the gut (16, 20).     
 
Figure 1. Bacterial Density and Diversity in the Gut. 
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1.1.5 Functions of Gut Bacteria  
Gut bacteria are frequently called commensals inferring that they are akin to non-rent paying 
tenants, when in actuality they are mutualists conferring many benefits to the host. The co-
evolution of bacteria and vertebrates has resulted in a relationship where the normal function of 
the host gastrointestinal organ system is dependent on gut bacteria for normal function (12). The 
human microbiota encodes one hundred times as many genes than the human genome in its 
entirety (20). The extensive gene pool within the gut microbiota enables gut bacteria to 
participate in metabolism, intestinal function, colonization resistance, and immune system 
development.  
Gut bacteria are major players in host metabolism with unique fermentation capacity. Gut 
bacteria metabolize complex plant polysaccharides and mucus that would otherwise be 
indigestible forming short chain fatty acids (SCFA) that are consumed by host cells for energy. 
The SCFA are acetate, propionate, and butyrate produced in a ratio of 60:25:15 (5, 10). Heart, 
muscle and brain cells utilize acetate, the liver uses propionate, and enterocytes use butyrate 
(20). Bacteroidetes are associated with carbohydrate metabolism whereas Firmicutes possess 
genes encoding transport systems for carbohydrate substrates (6, 10, 12). Moreover, gut bacteria 
function to metabolize amino acids, xenobiotics, and synthesize essential vitamins (i.e. vitamin 
K, biotin) (2, 4, 5, 19, 20).  Collectively, the metabolic potential of the microbiota is thought to 
mimic that of the liver (4).  
In addition to the basic metabolic functions performed by gut bacteria, hosts receive aid 
with intestinal development, immune system development, and colonization resistance from their 
abundant neighbors (10, 11, 18). Regarding intestinal development, gut bacteria increase 
mucosal thickness, increase crypt depth, and cause broader and shorter villi thereby increasing 
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the over mass of the small intestines (5). Moreover, gut bacteria promote intestinal epithelial cell 
turnover, mucus production, and peristalsis (5). The development of the mucosal immune system 
is only partially driven by intrinsic factors and requires cues from gut bacteria for full 
development (2, 3, 5). Studies in Germ Free rodents underscore the importance of gut bacteria to 
host immunity and will be discussed more extensively later.  Lastly, just by being present, the 
gut microbiota function to prevent proliferation and establishment of new bacteria strains by 
competing for space and resources (4, 5, 7, 9, 12, 19). Loss of colonization resistance is a 
common side effect of antibiotic therapies that essentially reduce bacterial density and alter 
community structure (7). In summation, the functions of the gut microbiota are numerous and 
likely incomplete as further studies continue to examine host-microbial interactions.  
1.2 BACTERIAL TRANSLOCATION 
In order to maintain the homeostatic and delicate relationship between the intestinal 
compartment and gut bacteria, the host skillfully implores several physical and immunological 
components to restrain residential microbial communities. Without these defenses, the host 
would succumb to infection, illness, and possibly death terminating the mutualistic relationship. 
At the physical level, the gut is characterized by a single layer of epithelium enforced by tight 
junctions, intermediary junctions, and desmosomes between cells (4, 23). The tight junctions 
restrict macromolecules with their small pore size permitting passage of molecules < 600 
Daltons (23). Barrier function is reinforced by a lubricating mucus layer, which serves to prevent 
bacteria from directly adhering to epithelium and invading the single cell layer (4, 19). 
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Antimicrobial molecules (i.e. α-defensins) produced by paneth cells further strengthen barrier 
function in the mucosal compartment (4, 19, 24).  
The gut barrier works in concert with the mucosal immune system to limit gut bacteria to 
the intestinal lumen. Both IgG and sIgA are produced in the mucosal compartment in response to 
colonization. Secretory IgA blocks adherence and penetration of bacteria to and past the 
intestinal epithelium (4, 25). Bacteria that bypass the gut barrier are rapidly removed by 
macrophages within the lamina propia immediately underneath the epithelium (19). Dendritic 
Cells patrolling the mucosal compartment occasionally sample gut bacteria, exit to mesenteric 
lymph nodes (MLN), and home back to the gut limiting their affects to the mucosal compartment 
(19). Peyer’s Patches (PP) and isolated lymphoid follicles (ILFs) also prevent bacterial 
translocation from the intestinal compartment. Some bacterial species co-localize with such 
structures in mice, non-human primates, and humans including Alcaligenes faecalis (25). The 
physical and immunological barriers of the gut effectively keep gut bacteria in their place.  
The intestine is not impermeable despite the wall created by the gut barrier. The intestine 
forms a selective barrier, permitting fluxes of nutrient, ions, water, and even dietary antigens 
(23). Intestinal permeability is facilitated by para-cellular diffusion and trans-cellular transport 
(23). Dietary antigens and bacterial products potentially travel between cells or across cells (23). 
Bacterial translocation to extra-intestinal compartments has rarely been proven in the healthy 
state (26). However, several factors can predispose to bacterial translocation including host 
immunodeficiency, stress-induced increases in intestinal permeability, enteric nervous system 
input regulating tight junction synthesis, manipulation of the gut during abdominal surgery, 
alteration of microbial communities (2, 4, 23, 26, 27). Compromised barrier function and/or 
increased intestinal permeability result in bacterial translocation.  
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Bacterial translocation is the exception, not the rule. Nonetheless, perturbations in the gut 
microbiota and gut barrier function ultimately lead to bacterial translocation and infection or 
exacerbation of concomitant diseases. For example, antibiotic therapy reducing competitors of 
Clostridium difficile promotes expansion of this intestinal colonizer and causes diarrheal illness 
plus mucosal injury (5). Likewise, bacterial translocation often results in bacteremia and 
septicemia in neonates with incompletely established gut microbiota (5). Characteristically non-
pathogenic colonizers (i.e. Enterobacteriaceae) could potentially translocate given the right 
conditions, but obligate anaerobes rarely translocate from the gut lumen, as the oxygenated 
environment of extra-intestinal tissues would not be suitable for survival (5).   
1.3 MICROBIAL DETECTION 
1.3.1 Microbiota Ignorance  
In spite of the gut bacteria preventing bacterial translocation, the peripheral body is not ignorant 
of gut bacteria. Historically, mice were thought to be systemically ignorant of microbiota based 
on the inability of colonizing gut bacteria to induce a humoral response with specific IgG 
production (19). However, absence of antigen specific IgG toward for microbiota members does 
not preclude gut-derived microbe-associated molecules from being able to stimulate systemic 
immunity. In fact, a broader influence of gut microbiota in the regulation of systemic immunity 
resulting from translocation of luminal bacterial products but not viable bacteria into systemic 
circulation is a growing area of interest (28). Further, Macpherson et al. proposed that the 
baseline setting of the immune system is a result of “contamination” of the body with microbial 
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products that have penetrated the gut barrier (19). This concept will reappear in the results 
section in relation to liver immunity development. 
 
1.3.2 Pattern Recognition  
In 1989, Charles Janeway proposed the idea of pattern recognition. He suggested that hosts 
should be able to detect conserved structures specific to microbes but not eukaryotic hosts (29, 
30). He postulated that these “pathogen-associated molecular patterns” distinguishable from self, 
or PAMPs as they are commonly called, would also have to be common to a broad class of 
microbes so they could be detected by a set number of receptors and that the structures would be 
required for microbe survival otherwise selective pressures would promote their mutation and 
evasion from detection (31). Truthfully, the innate immune system relies heavily on the 
recognition of the evolutionarily conserved microbial structures (PAMPs) through a limited 
number of germ-line encoded pattern recognition receptors (PRR) just as Janeway proposed over 
20 years ago (32). While PAMPs, by definition are supposed to be highly conserved, microbes 
do show significant diversity in PAMPs that may influence how they are recognized (33). The 
current understanding of microbe-PRR interaction was catapulted by the discovery of Toll-like 
Receptors (TLR) in 1997 (32). Since then the concept of PAMPs has been criticized because 
PAMPs are not restricted to pathogens and are present on all members of the microbiota, most of 
which are not pathogenic or virulent, and were subsequently renamed “microbe-associated 
molecular patterns”  (MAMPs) (33). As our understanding of pattern recognition grows, PRR 
have been shown to recognize danger signals or “damage-associated molecular patterns” 
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(DAMPS), which mediate sterile inflammation (32, 34) as well as ligands that orchestrate host-
commensal symbiosis labeled “symbiont associated molecular patterns” (SAMPs) (35). 
Pattern recognition and the resulting downstream response is confounded by whether or 
not the host distinguishes between pathogenic and nonpathogenic microbes, detection of single 
MAMPs by multiple sensors, detection of multiple MAMPs by single sensors, coincident 
detection of multiple MAMPs by multiple sensors, and where in the host the MAMP is detected 
(30-33). The advantage of having multiple PRR recognize different components of a single 
microbe as well as different classes of microbes prevents immune evasion (32). The location 
within the body and within individual cells (extra-cellular, endosomal compartment, or cytosol) 
also provides information as to how a particular MAMP should stimulate the host.  
Pattern recognition can affect the host in a multitude of ways. PRR, upon binding to 
specific ligands, often trigger pro-inflammatory and antimicrobial responses via activation of 
intracellular signaling pathways. The downstream signaling pathways of individual PRR are 
similar to each other and consist of recruitment of adaptor molecules, kinases, and activation of 
transcription factors (32). The two major categories of responses induced by MAMPs are 
transcriptional (i.e. gene expression) and post-translational (activation of genes expressed) (33). 
The end-result of PRR signal transduction includes (but is not limited to) the synthesis of 
cytokines, chemokines, adhesion molecules, immunoreceptors, and recruitment of leukocytes (4, 
32). Recognition of MAMPs by PRR on antigen presenting cells (APC) like DC and KC triggers 
cytokine production, co-stimulatory molecule expression, and activation of T cells (4). 
Therefore, PRR-MAMP interactions are not only important for innate immunity and infection 
clearance, but also bridges to adaptive immunity.  
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How the immune system differentiates between the microbiota and infectious microbes 
remains an unanswered question (35). One theory is that host cells can distinguish between 
pathogenic live bacteria and dead or non-threatening bacteria/MAMPs based on the PRR that are 
activated. Live virulent bacteria are more equipped to penetrate the cell cytoplasm or secrete 
virulent factors into the cytoplasm (via type 3 secretion systems), where they may be detected by 
cytosolic PRR (33). Another theory is that infectious replicating bacteria release more MAMPs 
or shed concentrated MAMPs at the site of infection initiating a different response than that 
elicited by the translocation of MAMPs from the gut microbiota. Moreover, endocytosed bacteria 
or MAMPs are degraded into a form recognized by specific endosomal PRR and are typically 
not seen by cytosolic PRR. Therefore the delivery of MAMPs to specific cellular compartments 
ultimately directs the response. Subsequent sections describe the most well characterized PRR-
ligand interactions.  
 
1.3.2.1 Transmembrane Pattern Recognition Receptors  
TLR are the most extensively studied receptors under the umbrella of pattern recognition 
receptors. TLR are homologs of Drosophila melanogaster’s Toll family of proteins, which also 
function to detect microbes (36). The Toll protein of Drosophila was characterized for its 
involvement in dorso-ventral patterning, but was later found to be important to the antifungal 
response in the fruit fly (32, 36). TLR are key components of innate immunity triggering host 
antimicrobial responses when activated (37). As a subset of PRR, TLR function to recognize a 
broad spectrum of MAMPs.   
TLR resemble each other in structure with common organization. They possess an extra-
cellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain 
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contains leucine rich repeats (LRR domain) (4). The LRR domain functions specifically in 
MAMP recognition either through direct binding or interaction with adaptor molecules. The 
LRR domains of TLR are horseshoe shaped and ligands may bind to both the convex and 
concave faces (29). The transmembrane domain connects the intracellular domain to the 
extracellular domain of TLR. The intracellular domain is called the TIR (Toll/IL-1R) signaling 
domain due to its homology to the IL-1 receptor (29, 32).  
TLR initiate intracellular signaling upon ligand recognition. Signaling pathways involve 
primarily adaptor protein recruitment, and activation of mitogen activated protein kinase 
(MAPK) and transcription factors. The major adaptor protein for all TLR except TLR-3 is 
Myeloid Differentiation factor-88 (MyD88) (32, 38). MyD88 allows association of IRAK-1 (IL1 
Receptor Associated Kinase) with the TIR domain (39). Other adaptor proteins that are recruited 
to the TIR domain include TIRAP (TIR domain containing Adaptor Protein), MAL (MyD88 
Adaptor Like protein), TRIF (TIR domain containing adaptor protein Inducing IFNβ), TICAM 
(TIR domain Containing Molecule-1), and TRAM (TRIF Related Adaptor Molecule) (38). 
Alternatively, TLR-3 signaling relies on TIR domain interaction with TRIF and not MyD88 (32). 
Association of adaptor molecules with the TIR domain of activated TLR allows activation of 
MAPK, p38, ERK, and JNK (30, 38). Ultimately, inhibitor of NF-κB is released following 
phosphorylation, which allows NF-κB to translocate to the nucleus where it can transcriptionally 
regulate the expression of hundreds of genes involved in the inflammatory and antimicrobial 
responses. In addition to NF-κB activation, TLR signaling activates members of the Interferon 
Regulatory transcription factor (IRF) family for the production of Type 1 Interferons (32).  
 Mammals have approximately eleven TLR that are restricted to cell membrane and 
endosomal compartments and are not involved in the detection of cytosolic MAMPs (32, 37, 39). 
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TLR-1, -2, -4, -5, -6, and -10 are located on the cell membrane (32). TLR-3, -7, -8, and -9 are 
found in the endosomal compartment (32).  TLR-11 is non-functional in humans, but functions 
in protozoan detection in mice (32). TLR-10 is expressed in humans, but not in mice (40). TLR-8 
is expressed in both humans and mice, but does not signal in mice (40).  
TLR expression patterns differ by tissue and cell type and can be influenced by genetic 
background. TLR expression has been documented in the intestine, liver, heart, kidneys and 
lungs (41, 42). Further, TLR expression has been described in epithelial cells, endothelial cells, 
neutrophils, T cells, B cells, NK cells, Dendritic Cells, Monocytes, and Macrophages (37, 39).  
Transmembrane PRR are not exclusively TLR. Alongside the surface TLR is also the C-
type lectin Dectin-1, which functions to detect the MAMP beta-glucan of fungus (31). See Table 
1 for transmembrane PRR and their respective ligands. Collectively, TLR can be classified 
according to the type of ligand they bind, whether they bind directly to their ligand (i.e. TLR-5) 
or require adaptor molecules (i.e. TLR-4), whether they bind a single ligand (i.e. TLR-9) or 
multiple ligands (i.e. TLR-2), and whether they form homo-dimers (i.e. TLR-5) or hetero-dimers 
(i.e. TLR-1/2). The broad range of TLR recognition allows TLR to alert the host to the presence 
of a diverse range of microbial products including bacterial, fungal, and viral MAMPs as well as 
host factors (DAMPs).  
The end result of TLR ligation is induced gene expression and post-translational 
modification of expressed genes, which trigger inflammatory and antimicrobial responses. For 
example, IL-6 and IL-12 production follow TLR activation and mediate the inflammatory 
response (38). Conversely, TLR-2 signaling contributes to IL-10 production and elicits an anti-
inflammatory response (35). Moreover, the induction of Type 1 Interferons (i.e. IFNβ) by TLR-3 
and -4 confers viral protection to the host (32, 39). Besides the transcription of genes that 
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promote cytokine/chemokine production, TLR ligation promotes the differentiation/activation of 
immune cells. TLR signaling favors Th1 skewing over Th2 (43). TLR signaling results in 
upregulation of MHC Class II and co-stimulatory molecule expression on APC (12). Even IgG 
antibody production by B cells can be TLR dependent in specific circumstances (31). Because 
hundreds of genes can be expressed in response to various MAMPs, transcribed genes should 
require multiple levels of regulation within the TLR pathway (44). 
Notably, immunodeficiency diseases have been linked with impaired TLR signaling, only 
further substantiating how critical MAMP detection is to the host. Mutations in NEMO, IκBα, 
IRAK4, MyD88, and TLR-3 causing immunodeficiency have been documented in humans (32). 
TLR SNPs have also been identified, although their role in inflammatory responses remains 
controversial. SNPs Asp229Gly and Thr399Ile in TLR-4 are associated with a blunted TLR 
response (45), but TLR-5 stop polymorphism is associated with protection from Systemic Lupus 
Erythematosus (46). Therefore, there are some deficiencies in the current understanding of the 
benefits and drawbacks of TLR in immune-related diseases.  
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Table 1. Transmembrane Pattern Recognition Receptors 
PRR Location Ligand 
TLR-1/2 Cell Membrane Bacteria: Triacylated Lipopeptides 
Synthetic: PAM3CSK4 






Bacteria: Lipotechoic Acid (LTA) 
Bacteria: *Peptidoglycan (PDG) 
Virus: Glycoprotein 
Virus: CMV, HSV  
Self: Heat Shock Proteins (HSP) 
TLR-2/6 Cell Membrane Fungus: Zymosan 
Bacteria: Diacylated Lipopeptides 
TLR-3 Endosome Virus: dsRNA 
TLR-3/7 Endosome Virus: RNA 
TLR-4 Cell Membrane 
Early Endosome 
Fungus: mannan 




Self: ECM products (Fibronectin, etc) 
Synthetic: Eritoran (Antagonist) 
Synthetic: TAK-242 (Antagonist) 
Other: Free Fatty Acids 
TLR-5 Cell Membrane Bacteria: Flagellin 
TLR-7 Endosome Virus: ssRNA 
TLR-8 Endosome Virus: ssRNA 
TLR-9 Endosome Bacteria: Unmethylated CpG motifs (DNA) 
TLR-10 Cell Membrane Unknown 
TLR-11 Cell Membrane Unknown 
References: (27, 32) (38, 39) (29, 30, 36, 40, 43, 45) (4, 46) 
*Unclear if PDG is recognized by TLR2 because of contradictory reports in the literature. 
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1.3.2.2 Cytosolic Pattern Recognition Receptors  
PRR stationed in the cell cytoplasm complement the TLR localized to the cell membrane and 
endosomal compartments. Cytosolic PRR consists of NOD-like Receptors (NLR), RIG-like 
Receptors (RLR), and others that have recently been identified but do not share homology with 
NLR or RLR.  The commonly studied NLR include NOD1 and NOD2 which both contain a 
nucleotide-binding oligomerization domain (NOD) and function to detect PDG (30, 32, 47). Two 
other newly identified member of NLR family include Ipaf (NLRC4) and Naip5, which both 
function to detect cytosolic flagellin (30). NLR have conserved structures like TLR, consisting of 
a centrally located NOD, a LRR domain on one end for ligand sensing, and a CARD domain on 
the other end that initiates signal transduction. Like NLR, RLR also have a CARD domain, but 
they differ by having a central helicase domain instead of the NOD domain found on NLR (32). 
The RLR family includes RIG-1 and MDA5 (Melanoma Differentiation Associated gene 5), 
which are both RNA helicases and function to detect exogenous cytosolic RNA (31, 32).      
Like TLR, NLR expression differs by tissue and cell type. NOD2 has been found on 
monocytes, macrophages, T cells, dendritic cells, granulocytes, intestinal epithelial lymphocytes, 
and hepatocytes just to name a few (48). However, expression of Ipaf is limited to cells of 
myeloid lineage (30). NLR expression has not been as extensively studied as TLR expression. 
The MAMPs detected by cytosolic PRR are nearly as diverse as those detected by TLR. 
PDG actually binds to two members of the NLR family, both NOD1 and NOD2 (49). However, 
NOD1 and NOD2 differ in the particular residues of PDG that they recognize. Diaminopimelic 
acid (DAP) of gram-negative bacteria binds NOD1 and Muramyl Dipeptide (MDP) of gram-
negative and gram-positive bacteria binds NOD2 (26, 32, 47, 48). NOD2 mutations are 
associated with Crohn’s disease and juvenile granulomatous diseases (31, 32).  
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Two other NLR, NALP1 and NALP3, also recognize the bacterial cell wall component 
PDG (MDP specifically). In addition, NALP3 detects host uric acid crystals, ATP, viral RNA, 
and bacterial DNA (32). As for RLR, RIG1 detects short viral dsRNAs and MDA5 detects long 
viral dsRNAs (31, 32). Cytoplasmic viral and bacterial DNA is recognized by two DNA sensors: 
AIM2 and DAI (DNA dependent activator of IFN regulatory factors) (32).  
Unlike TLR activation upon MAMP detection, cytosolic PRR activation typically leads 
to inflammasome formation and cleavage of pro-molecules versus the transcription/translation of 
new antimicrobial and inflammatory molecules (33) although NLR signaling does induce the 
secretion of pro-inflammatory cytokines IL-6 and IL12 (30). The activation of pro-molecules via 
NLR signaling is mediated through the activation of caspase 1 (30). Caspase 1 can functionally 
cleave molecules like pro-IL1β and pro-IL-18 into the active forms of these cytokines. Aberrant 
IL-1 production associated with NLR mutations results in periodic fever syndromes (32).   
Another mechanism of NLR signaling that differs from TLR signaling is pyroptosis.  
Pyroptosis is programmed cell death that differs from apoptosis and is primarily mediated by 
caspase 1 functioning to protect “damaged” cells and limiting “infection” spread (30). Similar to 
TLR signaling, RLR activation leads to Type 1 Interferon production mediating the cellular anti-
viral response (32).  The characteristic diversity, functional redundancy, and sheer frequency of 
TLR, NLR, RLR and other MAMP sensors is astonishing.  
1.3.3 Microbe-Associated Molecular Patterns of Interest  
1.3.3.1 Peptidoglycan  
Peptidoglycan (PDG) is a structural component of bacterial cell walls. Although, cell walls are 
characteristic of gram-negative bacteria, both gram-negative and gram-positive bacteria have a 
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layer of PDG (26). In gram-negative bacteria, PDG is located under the bacterial outer 
membrane that contains LPS (4, 32). PDG is formed by polymerization of alternating N-
acetylglucosamine and N-acetylmuramic acid residues connected by a short stem peptide made 
of diaminopimelic acid (DAP) (49). As mentioned previously, monomeric components of PDG 
include DAP and MDP which are recognized by PRR (NOD1 and NOD2 respectively). 
Lysozymes, secreted by the host, are bacteriocidal effectively liberating muropeptide fragments 
including DAP and MDP from the bacterial cell wall (50). Then, PDG recognition proteins 
(PGRP) pick up soluble PDG residues that are released upon bacterial degradation (51).  
Alternatively, PDG fragments can be released during bacterial cell wall synthesis occurring 
during bacterial replication (50).  
Clark et al. demonstrated that luminal PDG can efficiently cross the gut barrier and enter 
systemic circulation and penetrate the bone marrow of hosts (12, 28). The natural structure of 
PDG following translocation is unknown at this time (26), although PRR can detect polymer 
PDG as well as monomers DAP and MDP. We also do not know of translocated PDG enters the 
cell cytoplasm to be picked up by NLR, although PDG-specific transporters PEP1 and PEP2 
have been identified in the gut and lungs respectively (50). We do know that PDG is detectable 
in healthy patient plasma (1.76 µg/mL) (26) and can conclude that PDG is present in circulation 
under homeostatic conditions. 
1.3.3.2 Flagellin  
Flagellin (FLA) is a major subunit of the fllament component of bacterial flagella (39). The 
entire flagellum is comprised of a basal body, hook, motor, and filament (39) and these 
components together make a whip-like structure on both gram-negative and gram-positive 
bacteria enabling their motility (30). FLA itself is shaped like a boomerang and consists of four 
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domains (D0-D3) that resemble the capital Greek letter gamma (Γ) (30). Of the four domains, 
one is a polymerization domain, one a signaling domain, and the remaining are hypervariable 
domains (39). An estimated 30,000 subunits of FLA are required to form the filamentous portion 
of a single flagellum (30).  
As previously mentioned, FLA is recognized by two major PRR, one inside the cell (Ipaf) 
and one on the cell membrane (TLR-5). The D1 domain of FLA binds directly to the concave 
face of TLR5 despite the isolation of this domain within the flagellar filament (30). Virulent 
bacteria utilize T3SS and T4SS to secrete FLA into the cell cytoplasm where it can be detected 
by Ipaf (30). Regardless of the PRR that detects FLA, NF-κB activation will result upon ligation 
and the subsequent response is largely cell/tissue specific. As little as 1µg of FLA was sufficient 
to elicit NF-κB activation in murine livers, but maximal NF-κB activation has been achieved 
with just 10ng in the lung (41). The degree of NF-κB activation induced by FLA was lowest in 
the lungs and intestines and highest in the liver of the murine organs examined by Rolli et al. 
(41). Accordingly, the highest level of TLR-5 expression was found in the liver, although TLR-5 
expression did not increase following exposure to exogenous FLA (41).  
The significance of FLA-PRR interactions on host health was made obvious by TLR-5 
knockout studies and in vivo FLA challenges by various groups. TLR-5 knockout mice have 
altered microbiota composition (12) as well as a five-fold increase in microbiota density (46). 
Moreover, TLR5 knockout mice display hyperphagia and hallmarks of metabolic syndrome for 
reasons not completely understood (12). Further, flagellin has been consistently detected in 
plasma of septic patients at a concentration ranging from 2ng/mL to 20ng/mL (39, 42). The 
translocation of luminal FLA into circulation under homeostatic conditions has not been 
documented.  
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1.3.3.3 Lipopolysaccharide  
Lipopolysaccharide (LPS), commonly referred to as endotoxin, is composed of an O-linked 
polysaccharide attached to a hydrophobic Lipid A moiety by a non-repeating core polysaccharide 
(4, 32). The Lipid A portion is a phosphorylated disaccharide backbone acylated with fatty acids 
(32). The degree of phosphorylation and acylation determines the immunogenicity of this lipid 
moiety (32). Moreover, the Lipid A portion of LPS is one of the most potent MAMPs 
characterized and is responsible for the inflammatory response observed in endotoxic shock (32). 
Lipid A is highly diverse among gram-negative bacterial species and the particular isoform of 
lipid A dictates the binding affinity for its cognate PRR, TLR-4 (32, 33).   
Liberated LPS immediately associates with LPS binding protein (LBP), which facilitates 
the transfer of LPS to MD2 and association of CD14 with the LPS-MD2-TLR-4 complex to 
mediate TLR-4 signaling. High circulating levels of LPS are characteristic of septic shock and 
multi-organ dysfunction secondary to systemic inflammation (41). Moreover, plasma LPS 
concentrations are tightly correlated with patient survival in sepsis and liver deterioration in 
patients with cirrhosis (26, 52). Even small amounts of LPS (as little as 0.1 µg) can skew the 
immune response (39). The primary method of LPS detection in blood is the Limulus 
Amebocyte Lysate assay, which has a detection limit of 5pg/ml (26). However, the translocation 
of luminal LPS into circulation has not been reliably reported using this assay. Kim et al. 
reported LPS detection in half of the healthy control patients enrolled in their study (26).  Crispe 
et al. report concentrations of LPS in portal blood up to 1 ng/ml under normal conditions, but no 
LPS in systemic circulation (53). Gregory et al. reported a LPS concentration ranging from 10-
1000pg/ml in portal venous blood (54). Yet, Singh et al. later reported that LPS was undetectable 
in normal rats and healthy humans (27). Accurate determination of LPS translocation from the 
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gut is likely complicated by: (1) interfering molecules such as CD14, LBP, and lipoproteins (26), 
(2) circulating cells expressing TLR-4 that trap LPS (26), and (3) the uptake of luminal LPS into 
gut-derived chylomicrons, which is often overlooked (55).   
1.3.4 Pattern Recognition Receptor Regulation  
PRR signaling must be tightly regulated due to the convergence of PRR pathways into the 
inflammatory response. Inducible negative regulators, production of anti-inflammatory 
cytokines, and alterations in PRR signaling complexes function as the “off switch” for PRR-
associated inflammation (44). PRR left “on” for too long will result in non-specific tissue 
damage (40). Examples of negative PRR regulators include PI3 kinase (interferes with TLR-5 
signaling), ST2, RP105, SARM, MyD88s (competes with MyD88), IRAK-M, Tollip, and SOCS 
(suppressors of cytokine signaling) (30, 32, 40).  
Although different classes of genes may be induced by the same PRR, their regulation 
does not appear to be at the signal level (44). Foster et al. performed a microarray on 
macrophages that were stimulated with LPS once, stimulated with LPS twice, or left un-
stimulated (44). Resulting gene expression from this experiment was then grouped into two 
classes: one gene set could only be elicited after a single LPS stimulation and not thereafter and 
the other gene set could be induced after a single LPS stimulation and was induced at ≥ 
magnitude with a second LPS stimulation (44). The gene set that was silenced after a single 
stimulation consisted mostly of inflammatory genes, while the gene set that was inducible over 
and over was comprised of antimicrobial genes. The induction of particular gene sets and the 




1.3.5 Pattern Recognition Receptor “Tolerance”  
PRR “tolerance” or hypo-responsiveness is characterized by poor inflammatory mediator 
production and can be mediated by several TLR. The lack-luster response of TLR-bearing cells 
following multiple stimulations or prolonged stimulations with a specific MAMP produces a 
“tolerant” or hypo-responsive state. Previous studies suggested this phenomenon was due to 
receptor desensitization (44). However, when trying to unravel the differential regulation of gene 
sets activated following TLR activation, Foster et al. elucidated the mechanism behind TLR 
tolerance as well (44). At present, it is clear that gene specific regulation following TLR 
activation occurs at the level of chromatin and includes nucleosome remodeling and covalent 
histone modification (44). Simply put, negative transcriptional regulators induce chromatin 
remodeling and loss of inflammatory gene expression with repeated TLR stimulation (44). The 
chromatin modification model was developed while examining the TLR-4 pathway, but this 
model can certainly be applied to other TLR that exhibit “tolerance.” Key examples of MAMP 
tolerance occur with TLR-5 ligation with FLA and TLR-4 ligation with LPS. Both receptors 
elicit reduced inflammatory cytokine production for a short period (hours to days) following 
repetitive stimulation with their cognate ligands and even reduce responsiveness to unrelated 
PRR agonists during this period (39, 40). PRR “tolerance” can be exploited therapeutically to 
manipulate host-microbial interactions.  
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1.3.6 Pattern Recognition Receptors in the Liver  
Some would agree that no obvious inflammation occurs in the healthy liver (40). By definition, 
inflammation infers that something has gone awry. Yet, the healthy liver in rodents and humans 
accommodates a multitude of cells that express various PRR and encounters translocated 
MAMPs in every day life. The next section will cover the various cells of the liver (with 
emphasis on Kupffer cells), but in order to set the scene-Table 2 describes the dangers of TLR 





















Table 2.  Pattern Recognition Receptors and Liver Pathogenesis 
TLR Condition Reference 
NOD2 Con A hepatitis (48) 




TLR-3 Attenuates Liver regeneration (51) 
TLR-4 Attenuates Acetaminophen-induced Injury 




Hepatocellular Carcinoma (HCC) 














Autoimmune Hepatitis (AIH) 
Primary Biliary Cirrhosis 






















1.4 THE LIVER AND NONPARENCHYMAL CELLS 
1.4.1 The Liver 
1.4.1.1 Blood Supply and Liver Architecture 
The liver is the largest solid organ in the body (54, 56-58). On gross examination, the liver 
appears to be a large red (well-perfused) organ located in the upper right quadrant of the 
abdomen under the diaphragm. Histologically, the liver appears to be a homogenous section of 
hepatocytes with occasional sighting of vascular tissue and bile ducts (59). The liver has multiple 
connections to the body’s vasculature, with two major entryways and one exit for circulating 
blood. Blood supply to the liver depends on the hepatic artery (branch from abdominal aorta), 
which provides oxygenated blood and supports bile ducts and tissues of the hepatic portal tract 
(53, 60). However, the majority of the liver’s blood supply comes from the portal vein, a 
confluence of the splenic and superior mesenteric veins. The liver receives 80% of its blood from 
the portal vein, the draining tributary of the intestines, spleen, and pancreas, and the remainder 
from the hepatic artery (57, 58, 61, 62). The hepatic artery and portal vein drain into liver 
capillaries also called hepatic sinusoids. Hepatic sinusoids form terminal hepatic venules that 
drain into the hepatic vein and then the inferior vena cava, which recirculates blood back to the 
heart (60, 61). The narrow diameter (5-7µm) of the liver sinusoids favors interaction between the 
liver’s cellular components and blood components (58, 60, 63). Our entire blood volume 
circulates through the liver about 360 times per day and a third of our blood volume passes 
through the liver each minute (58, 60, 63). Constant recirculating blood enhances exposure to 
gut-derived MAMPs (58).  
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Blood flows from portal tract (periportal region) to hepatic venule (centrilobular region) 
through the hepatic sinusoid, while bile flows in the opposing direction (64). The portal tract 
(portal triad) consists of a portal vein, bile duct, hepatic artery, lymphatic vessels, and 
sympathetic nerves too (59). The architecture of the liver is highly reflective of its function. The 
functional unit of the liver is the lobule and the cellular unit is the hepatocyte. Liver lobules are 
plates of hepatocyte in hexagonal arrangement (58, 64). The liver can be also divided by tissue 
system comprised of elements from the vascular system, hepatocytes, biliary cells, immune cells, 
and stroma (64). 
1.4.1.2 Cellular Components of the Liver 
The healthy liver is not considered to be inflamed (40). However, like primary and secondary 
lymphoid organs, the liver is enriched in various immune cell types capable of executing innate 
immunity functions (53, 58, 61). Immune cells found in the liver include Kupffer Cells (KC), 
Dendritic Cells (DC), Natural Killer (NK) cells, Natural Killer T (NKT) cells, and other 
lymphocytes (53, 56, 57, 63, 64). In addition to traditional immune cells, hepatocytes, biliary 
epithelial cells (BEC), and stellate cells (SC) also possess immunological function (61). 
Hepatocytes predominate the liver mass (60-80%) and constitute the parenchymal cell 
population. All other cells fall into the non-parenchymal cell (NPC) forming 20-40% of the 
liver’s cellular mass (65). The exact pattern of PRR expression and functionality in the liver has 
not been fully elucidated.   
1.4.1.3 Functions of the Liver 
The liver as its name indicates is essential for life. During the fetal period, the liver serves as 
hematopoietic tissue before maturing to function as the central organ for metabolism managing 
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exocrine, endocrine, and immunity responsibilities (56, 66). Liver functionality can be divided 
into two major groups: (1) metabolism-related and (2) immune-related. Firstly, the liver is 
responsible for protein, carbohydrate, and lipid metabolism as well as bile synthesis and drug 
detoxification (58). Secondly, the liver modulates PRR-MAMP interactions and also contributes 
to innate immunity via the synthesis of acute phase proteins (i.e. metallothioneins), cytokines, 
and chemokines (40, 56-58, 62, 65). Antimicrobial proteins like complement help the host 
combat viruses, bacteria, and tumors (56). The liver’s expansive number of immune cells help in 
this regard as well. 
As mentioned before, the liver functions in the metabolism and catabolism of dietary 
elements (63). Hepatocytes located within different zones of the liver carry out different 
metabolic functions. The acinar zones are prime location for β-Oxidation. Cholesterol synthesis 
takes place in the periportal region. Glutathione functions to protect hepatocytes from oxidative 
stress and is produced primarily in the periportal region (67). Urea and glutamine synthetase 
strictly occur around the central veins (67). Bile synthesis is highest in central areas too (67).  
The secreted immune-related proteins are diverse and possess many functions, all of which 
will not be covered. However the acute phase proteins and complement proteins are of particular 
interest. The production of acute phase proteins is best characterized during infection and 
inflammation, however the mechanism behind constitutive production of dozens of these 
proteins has not been elucidated (58). Still, the acute phase response is characteristic of innate 
immunity, rapid and non-specific, acting as a first line of defense before more specialized cells 
are recruited to resolve either infection, inflammation, or tissue injury (62). By definition, acute 
phase proteins synthesized by the liver must change their baseline concentration (up or down) by 
at least 25% in response to perturbations (62). Pro-inflammatory cytokines Interleukin-1, 
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Interleukin-6, and Tumor Necrosis Factor-α as well as glucocorticoids particularly enhance acute 
phase protein synthesis by hepatocytes, further enhancing the inflammatory response (62). 
Complement protein production confers cytotoxic, opsonization, and inflammatory function (57). 
Secreted soluble PRR made by the liver aid in microbial opsonization as well. The liver also 
serves as a scavenger to clear circulating antigens in order to prevent systemic inflammation (57, 
65). While assuming immunological responsibilities, the liver has to circumvent dispensable 
immune activation and tissue injury to maintain its metabolic function, which is essential for 
survival.  
1.4.2 Parenchymal and Non-Parenchymal Cells 
1.4.2.1 Parenchymal Cells 
Parenchymal cells perform the vast majority of metabolic processes carried out by the liver. 
Hepatocytes, parenchymal cells, are the predominant cell type of the liver representing 70% of 
hepatic cells and 80% of total liver volume (57-60, 64). Hepatocytes form anastomosing plates of 
cells of one cell thickness and communicate with each other via gap junctions (67). On one side, 
hepatocyte face the Space of Disse separated from the hepatic sinusoid by a layer of endothelial 
cells. On the other side, hepatocytes face the bile canaliculus responsible for bile collection (59, 
64).  
Hepatocytes are essentially synthesizing factories. They contribute to innate immunity by 
releasing soluble PRR, complement protein, and acute phase proteins into the blood stream (57, 
58, 62). Hepatocytes synthesize C1-9, Cbp, Factor B, mannan binding lectin, CfI, CfH, and C1 
inhibitor (57). Intra-hepatic immune cells make minor contributions to complement synthesis as 
well (57). Although hepatocytes are separated from the cells of the sinusoid by endothelial cells 
 33 
lining the sinusoid, hepatocytes do express MHC class I, Intercellular Adhesion Molecule 1 
(ICAM1), and CD1d (MHC Class 1-like molecule that engages the TCR of NKT cells). 
Therefore, hepatocytes have the potential to interact with lymphocytes (58, 62). Many have 
speculated that hepatocytes contribute to liver tolerance by inducing T cell death by neglect 
when engaging TCR (signal 1) but not providing co-stimulatory signals (signal 2) (53, 62), but 
the likelihood of hepatocytes engaging T cells in vivo under homeostatic conditions seems 
relatively slim considering liver architecture. Nonetheless, in the course of hepatic inflammation, 
T cells target hepatocytes for destruction (64).  
1.4.2.2 Liver Sinusoidal Endothelial Cells 
Liver Sinusoidal Endothelial Cells (LSEC) form half of the non-parenchymal cell (NPC) 
population in the liver (60, 68). Their lack of basement membrane and clusters of fenestrations 
(100nm) appearing like “sieve plates” facilitate communication between hepatocytes and 
sinusoidal content (53, 58, 62, 63, 66-68). LSEC differ from endothelial cells in other organs by 
their distinct pattern of adhesion molecules. For example, LSEC lack E-selectin and P-selectin, 
but constitutively express ICAM1, Vascular Adhesion Protein 1 (VAP1), and CD44 (LYVE1) 
(61, 63, 64, 69). ICAM1, VAP1, and CD44 are critical adhesion molecules involved in leukocyte 
recruitment to the liver (61).  ICAM1 and CD44 facilitate firm adhesion, while VAP1 facilitates 
brief rolling adhesion of leukocytes (61). ICAM1 binds to Lymphocyte Function-associated 
Antigen 1 (LFA1 also known as CD11a) found on lymphocytes, macrophages, and neutrophils 
(62). Further, VAP1-leukocyte interactions upregulate ICAM1 (CD54) and VCAM1 (CD106) 
expression on LSEC (61). VCAM1 interacts with the integrin CD49d on lymphocytes (63). 
VCAM1 and MadCAM1 (the gut homing adhesion molecule) are inducible under inflammatory 
conditions (61, 70). In addition, LSEC express numerous ligands for chemokine receptors found 
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on circulating leukocytes including CCL3-5, CXCL9-11, and CXCL16 (61, 64). Both 
constitutive adhesion molecule expression and chemokine expression enable accumulation of 
liver leukocytes.  
LSEC have been characterized as non-immune cells with immune function. Whether 
LSEC actually serve as APC remains a point of contention (53, 62). LSEC have the most 
potential of all of the liver cells to interact with circulating leukocytes (63, 65). Moreover, LSEC 
express MHC class I, MHC class II, and costimulatory molecules CD40, CD80, and CD86 (53, 
58, 60, 63, 71). Moreover, LSEC undoubtedly produce both pro-inflammatory cytokines (i.e. IL-
1) and anti-inflammatory mediators (i.e. IL-10, PGE2) (53, 62, 63). LSEC also clear 
macromolecules from circulation (53, 58, 60, 62). At least five different endocytosis receptors 
have been identified on LSEC, which can function in antigen uptake (57).  
1.4.2.3 Biliary Epithelial Cells 
The liver houses specialized cells, Biliary Epithelial Cells (BEC), which function to transport 
bile. Bile leaves the liver and is stored in the gall bladder. Bile is released into the intestine, in 
response to dietary fat consumption, where it functions to emulsify fats for breakdown and 
uptake. BEC only make up a small amount of the total liver mass in comparison to other NPC 
like LSEC (62). Notably, BEC do express PRR to detect invading microbes in the bile ducts 
(58). Despite their low frequency, BEC are specifically targeted in liver diseases such as Primary 
Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis, and vanishing bile duct disease (62).  
1.4.2.4 Dendritic Cells 
Intra-hepatic Dendritic Cells (DC) are derived from the bone marrow (60, 62). DC frequency 
within the liver is sparse, but are can be identified around portal tracts (58, 62). The liver 
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contains five types of DC: myeloid DC (CD8α-B220-CD11b+), lymphoid DC (CD8α+B220-
CD11b-), plasmacytoid DC (CD8α-B220+), a mixture of lymphoid and myeloid DCs (B220-
CD11-) and natural killer DC (B220-CD11cint CD69+2B4+DX5+) (53, 57, 58). Plasmacytoid DC 
are more abundant in the liver than in the spleen (53). Notably, lymphoid and natural killer DC 
are specific to rodents livers and have not been identified in humans (53). 
Intra-hepatic DC are the only professional APC present among NPC (62, 65). Activated 
DC migrate to the space of Disse to exit into the lymphatic system where they are then 
transported to extra-hepatic lymph nodes for initiation of adaptive immunity (62). Liver DC are 
poor T cell stimulators in comparison to extra-hepatic populations of DC (i.e. spleen and bone 
marrow derived DC) (57, 58, 62). Their poor immunostimulatory capacity is attributed to an 
immature phenotype and lack of costimulatory molecule expression (58, 60). The cytokine 
milieu in the microcirculation of the liver containing high amount of IL-10 appears to render 
residential DC tolerogenic (60, 62). Intra-hepatic DC are key players in the balance between 
immunity and liver tolerance given their poor immunostimulatory capacity yet efficient antigen 
capture and MAMP detection capabilities (58, 62).    
1.4.2.5 Hepatic Stellate Cells 
Hepatic stellate cells (SC), localized to the Space of Disse, make up 5-10% of NPC in the liver 
(65, 68).  SC, also called Ito cells and fat-storing cells, function to store vitamin A, store fat, and 
modulate hepatic microcirculation (58, 59). The ability of SC to function as APC is 
controversial, although they express MHC Class I, MHC Class II, and CD1d (58).  
SC are quiescent in the healthy liver (57). SC are activated in various liver pathologies. 
Upon activation, SC proliferate and acquire a myofibroblastic phenotype (57, 58). 
Myofibroblast-like SC secrete large amount of extracellular matrix proteins and collagens 
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thereby promoting liver fibrosis (57, 59, 65, 72, 73). SC can be activated by Kupffer Cells 
producing TGFβ and Platelet Derived Growth Factor (PDGF) (57, 72, 73). 
1.4.2.6 Mast Cells and Granulocytes 
In the healthy liver, granulocytes are rarely identified representing less than 1% of the liver NPC 
(54, 58). Mast cells are also extremely rare in the healthy liver and have not been identified 
consistently in humans and rodents in absence of liver pathology (58). Liver pathologies may 
recruit large numbers of granulocytes (neutrophils, basophils, and eosinophils) (58). 
1.4.3 Kupffer Cells 
1.4.3.1 Origin and Lifespan 
Kupffer Cells were identified by pathologist C. von Kupffer in 1876 (73, 74). In the 1970’s and 
1980’s, the mononuclear phagocyte system (MPS) was defined as a family of cells that includes 
bone marrow progenitors, circulating monocytes, and tissue macrophages (75). Circulating 
monocytes enter the liver where they differentiate into KC (60, 65, 75, 76). In the traditional 
MPS, cell division occurs at the level of the monoblast and proliferation of differentiated tissue 
macrophages rarely occurs (75). Ralph van Furth, the father of the MPS, provided evidence that 
tissue macrophages lacked self-renewing capabilities through thymidine incorporation assays 
(74, 75). Likewise, Croton et al. reported that less than 2% of Kupffer Cells proliferate under 
steady state conditions (76). 
The MPS is challenged by the separate embryonic phagocytic lineage (75). During the 
fetal period, macrophages are found in the yolk sac although they differ from adult macrophages 
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and do not express F4/80 (75). Although, the bone marrow compartment has not formed during 
the early gestational period, macrophages still appear in the liver, although they disappear at later 
developmental stages and then reappear at low frequency before birth (66). Additionally, some 
KC may be derived from the spleen based on splenectomy studies (77). Presently, there is no 
consensus on the lifespan of Kupffer Cells. KC may turnover after weeks or survive for up to a 
year (74, 76). 
1.4.3.2 Frequency 
Kupffer Cells account for 80-90% of all tissue macrophages in the body, 15% of liver cells, and 
20-35% of non-parenchymal cells (54, 58-60, 62, 68, 71, 73, 74, 76, 78). The sheer numbers of 
KC present in the liver signify their importance to this organ.  
1.4.3.3 Location and Distribution 
Kupffer Cells are localized to the hepatic sinusoid adherent to LSEC (54, 59-61, 63, 68, 74). KC 
have heterogeneous distribution within the liver and are consistently absent in the sinusoids 
within 50 microns of central veins (68). KC predominate in the periportal region (43%) and 
lesser so in the mid-zonal and centrilobular regions (25% and 29% respectively) (54, 58, 73, 77). 
Although KC are reportedly fixed macrophages, several groups have refuted the claim that KC 
are sessile, insisting that KC are in fact mobile within the sinusoid (63, 73, 78). 
1.4.3.4 Phenotype 
Although KC are localized throughout the liver, differences exist in phenotype based on 
proximity to the portal vein (74). Periportal KC are larger with higher lysosomal enzyme content 
and greater phagocytic potential compared to centrilobular KC (67, 74). Larger KC have been 
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shown to produce more TNFα, PGE2, and IL1 than smaller KC (74). Intermediate and large KC 
also release IL-6, IL-10, and MCP1 (monocyte chemotactic protein 1) to exert antimicrobial 
functions (58). Centrilobular KC are smaller and produce more NO (74). Smaller KC can also 
make TNF-α and may have a more prominent role in immunoregulation (58). 
F4/80 can be used as a pan-macrophage marker for tissue macrophages (68, 75, 77). The 
F4/80 antibody binds to family of seven transmembrane domain receptors (EMR1-4 in humans 
and EMR1-2 in mice) related to Epidermal Growth Factor found exclusively on macrophages 
(75). The F4/80 antigens are difficult to detect on lung, lymphoid, and fetal macrophages (75). 
The function of these receptors is unclear, but they bind to proteoglycans (68, 75). The ED1 and 
ED2 antigens, which function as hemoglobin scavenger receptors, are used to identify KC in rats 
(74). KC also exclusively express heme oxygenase 1, which is an inducible KC marker (74). 
There are few other surface markers that distinguish KC from professional APC like DC (75). 
When liver macrophages were being characterized in the 1970’s, investigators used esterase 
staining to non-specifically identify KC (76).  
 Several investigators (including myself) have tried to identify distinct subsets of liver 
macrophages by identifying phenotypic/functional differences. Two types of macrophages have 
been characterized outside of the liver termed M1 an M2. M1 macrophages are thought to be 
activated classically while M2 macrophages are activated by an alternative mechanism (61). M1 
macrophages make pro-inflammatory cytokines (i.e. IL-6) and anti-microbial products and M2 
macrophages make anti-inflammatory cytokines (i.e. IL-10) to promote tissue repair (61, 65). M1 
macrophages interact with Th1 cells (cellular immunity) and M2 macrophages interact with Th2 
cells (humoral immunity) (72). Alas, Kupffer Cells do not appear to polarize into M1 and M2 
subtypes (77). However, they may be divided into CD11b+ and CD11b- subsets based on 
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function. CD11b is found on myeloid cells, granulocytes, and NK cells and functions as a 
complement receptor. CD11b- KC appear to be less phagocytic, more sensitive to gadolinium 
chloride and liposome entrapped clodronate (macrophage depleting agents), and produce lower 
amounts of ROS, TNFα, and IL-12 following antigenic stimulation (77). The percentages of 
CD11b- versus CD11b+ KC have not reported (77). 
1.4.3.5 Function 
KC are phagocytes first and antigen presenting cells second. As phagocytes, KC clear the 
sinusoids of circulating debris, senescent erythrocytes, activated neutrophils, bacteria, LPS, 
immune complexes, chemicals, and injectable colloids (54, 57, 58, 62, 65, 68, 73, 74, 78). KC 
perform both immune and non-immune mediated phagocytosis to clear the sinusoid of insoluble, 
toxic, and infectious agents. Immune mediated phagocytosis is carried out using Complement 
and Fc Receptors (62). Non-immune mediated phagocytosis utilized opsonins and lectin 
receptors (62). In addition, KC partner with neutrophils to clear bacteria from circulation by 
adhering bacteria on their cell surface so that neutrophils can eliminate bound but not 
phagocytosed bacteria (63, 74).   
As antigen presenting cells (APC), KC present antigen to activated effector T cells via 
MHC class II, but not as efficiently as spleen macrophages or bone marrow derived macrophages 
likely for the same reasons that liver DC are poor APC (63, 65, 73). KC, within the hepatic 
sinusoid, are in a prime location to interact with lymphocytes as they pass through the liver (61). 
KC are important to innate immunity and host defense (52, 73, 74). They secrete many 
immune mediators to fulfill their immunological responsibilities, which affect the activity of 
neighboring cells (60). Cytokines reportedly produced by KC (constitutively or upon activation) 
include the following: TGF-β, TNF-α, IL-1, IL-6, IL-10, IL-12, and IL-18 (54, 60, 62, 63, 65, 
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71, 73). TNF-α, produced by KC in soluble or membrane-form, is a cytotoxic factor in the liver, 
which can cause hepatocyte death and promotes the infiltration of granulocytes to the liver (71). 
It is worth mentioning that both pro-inflammatory and anti-inflammatory cytokines are produced 
by KC when exposed to MAMPs (63). Moreover, the production of pro-inflammatory cytokines 
upregulate adhesion molecule expression by LSEC (61), while anti-inflammatory cytokines can 
downregulate MHC Class II and costimulatory molecule expression on KC and other NPC. KC 
also release leukotrienes, thromboxane A2 (TXA2), prostaglandin E2 (PGE2) and ROS, which 
may be immunosuppressive or immunostimulatory depending on context (54, 60, 63, 73). 
1.4.3.6 Activation 
Upon activation, KC characteristically produce pro-inflammatory cytokines, but also IL-10 
which serves a negative feedback mechanism to reduce TNF-α and IL-6 production and 
promotes liver tolerance (71). KC activators include ischemic injury, complement components 
C3a and C5a, MAMPs (i.e. LPS), and cytokines (74, 78). Prostaglandins typically suppress KC 
activation (78). The major signal transducer of activated KC is phospholipase C (PLC), which 
activates Protein kinase C (PKC) and NADPH oxidase (oxidative burst) as well as prostaglandin 
synthesis (PGE2 and TXA2) (74). Strong activation signals permit KC to activate T cells, 
leading to T cell proliferation (58). Activated KC producing IL-12 and IL-18 seem to be 
particularly important for the maturation of Natural Killer T (NKT) cells and subsequent IFN-γ 
production (60, 62, 71).  
One of the most intriguing characteristics of KC is their ability to become tolerant (hypo-
responsive) upon antigenic stimulation. KC depletion experiments have demonstrated that KC 
are involved in oral tolerance, portal venous tolerance, and liver allograft tolerance (53). KC 
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promote tolerance partially by inducing apoptosis of intra-hepatic T cells (74). The mechanisms 
behind KC mediated tolerance are not fully understood.   
1.4.3.7 The Good, The Bad, and The Ugly 
KC are implicated in many liver pathologies including Alcoholic Liver Disease (ALD), 
Nonalcoholic Fatty Liver Disease (NAFLD), Liver failure secondary to Acetaminophen (APAP) 
toxicity, and Ischemia/Reperfusion (I/R) injury (73, 74). In I/R injury, KC produce tissue 
damaging oxygen radicals and hepatotoxic TNF-α (73). Reperfusion activates KC, presumably 
via LPS buildup from portal vein occlusion during surgery (74). In hepatic fibrosis, KC produce 
SC activation factors (PDGF and TGF-β) driving myofibroblast production of extracellular 
matrix and reducing matrix metalloproteinases activity (72, 73). In ALD, KC are activated by 
LPS to produce excessive TNF-α and inflammatory mediators (73, 74). There is little evidence 
suggesting that alcohol actually affects KC, but overwhelming evidence showing increased LPS 
translocation from the gut secondary to alcohol mediated by increased intestinal permeability 
(73). Acute alcohol exposure affects KC differently than chronic alcohol exposure associated 
with ALD. In fact, pro-inflammatory cytokine production by KC is inhibited by acute alcohol 
exposure (74).  
There is a limited set of experimental models of liver inflammation. One of the major 
models of liver inflammation and fibrosis is mediated by Carbon Tetrachloride (CCl4). Activated 
KC cause more tissue damage than inactivated KC or the absence of KC in this model (73). 
Circulating monocytes differentiate into NO producing KC with chronic CCl4 exposure (72). In 
the model of hepatic inflammation mediated by APAP, KC are directly activated by 
acetaminophen and deplete liver glutathione stored causing tissue damage (74). KC further 
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exacerbate drug-induced liver injury by producing TNF-α, IL-1, and NO (61). Conversely, KC 
can be hepato-protective in the model of liver injury mediated by Concanavalin A (65).   
Increased Kupffer Cells frequency or activation does not have adverse consequences in 
all scenarios. For example, increased KC numbers allow for more efficient clearance of bacterial 
infections and resolution of septicemia in mouse models (73). In addition, KC prevent metastasis 
of GI primary tumors to the liver via phagocytosis of metastatic tumor cells (73, 74). Finally, the 
importance of KC in liver regeneration was demonstrated by KC depletion studies (74).  
1.4.4 Liver Lymphocytes 
The human liver houses 1010 lymphocytes (60, 62). The heterogeneous group of intra-hepatic 
lymphocytes is predominantly localized to the periportal regions of the liver, but lymphocytes 
are occasionally scattered throughout the parenchyma (62). Circulating lymphocytes travel into 
the liver to become resident lymphocytes and undergo maturation (62). Leukocyte recruitment to 
the liver was previously attributed to physical trapping in narrow sinusoids often obstructed by 
Kupffer Cells (61). However, lymphocytes have been shown to adhere to ICAM1 on LSEC 
under physiological conditions and ICAM1 knockout mice demonstrate reduced lymphocyte 
adhesion to hepatic sinusoids (61, 63). Leukocyte migration into the liver is also dependent upon 
the appropriate chemotactic gradient generated by chemokine produced by parenchymal and 
non-parenchymal cells (64).  
Intra-hepatic lymphocytes (IHL) are comprised of: T lymphocytes, B lymphocytes, 
Natural Killer (NK) cells, and Natural Killer T (NKT) cells. Conventional T lymphocytes 
include CD4+ and CD8+ T cells (65). Unconventional T cells are categorized according to NK 
cells markers (i.e. NKT cells) and those that do not (i.e. γδ T cells) (62). Nonetheless, over 80% 
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of intra-hepatic T cells express the αβ TCR leaving γδ T cells in the minority (62). In 
comparison to other organs, NK (30% of IHL) and NKT (20% of IHL) cells are particularly 
abundant in the liver (57, 62, 65). B lymphocytes only make up 6-10% of the IHL population in 
humans and rodents (58, 62). 
1.4.4.1 Hepatic B Cells  
Due to the small number of residential B cells in the liver, not much is known about their 
function (60). Traditionally, B cells are activated, differentiate, and proliferate in lymphoid 
organs (60). In the mouse, hepatic B cells are similar to B2 splenic lymphocytes (58). In humans, 
hepatic B cells are CD5+ and are distinctly different from murine hepatic B cells (58).  
1.4.4.2 Double Negative Hepatic T Cells  
Conventional hepatic T cells are typically CD4+ or CD8+ T cells. However, cells that express 
neither CD4 nor CD8 are double negative T cells, which are found in secondary lymphoid 
organs, the appendix, and the liver (58). This pool of T cells is extremely difficult to detect, 
hence not much is known about their role in liver immunity (62). 
1.4.4.3 Conventional Hepatic T Cells  
Conventional hepatic T cells comprise CD4+ and CD8+ T cells, which recognize antigens 
presented by MHC Class II and MHC class I respectively (60, 62). The liver differs from the 
periphery in that it possesses a higher proportion of CD8+ T cells relative to CD4+ T cells (58, 
60, 62). Hepatic CD8+ T cells that only express alpha chain of CD8 have been reported (62). The 
vast majority of hepatic T cells produce IFN-γ, IL-2, and TNFα (62). Few hepatic T cells 
produce IL-4 (62). 
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1.4.4.4 Hepatic Regulatory T Cells  
Regulatory T cells constitute less than 1% of the IHL population (79). In comparison to 
lymphoid organs like the spleen and draining lymph nodes, the liver has at least one hundred fold 
fewer FoxP3 expressing CD4+ T cells (58). The suppressive activity of regulatory T cells has 
been deeply investigated, however their role in liver tolerance and transplantation may be limited 
due to low numbers of cells (58). 
1.4.4.5 Hepatic Gamma Delta T Cells  
Gamma delta T cells differ from conventional T cells by expressing an alternative T cell receptor 
made of γ and δ subunits. Γδ T cells are abundant in the skin, the genitourinary tract, the gut, and 
the liver (57, 58, 62). In the liver, γδ T cells make up 15-20% of IHL (58, 62). The TCR of γδ T 
cells is thought to recognize a limited range of antigens although antigen recognition by γδ T 
cells is not restricted by MHC class I/II presentation, thus exact target of these cells in the liver is 
unknown (60, 62). This hepatic T cell subset may play a role in combating viral and bacteria 
infection (57). 
1.4.4.6 Hepatic Natural Killer Cells  
Hepatic Natural Killer cells, also called Pit cells, are 10% of liver lymphocytes in mice and 30-
50% of liver lymphocytes in humans (57). Natural Killer (NK) cells can be identified by the 
absence of the T cell marker CD3 and expression of CD56 (neural cell adhesion molecule 
isoform) in humans (58, 62). NK cells are large granular lymphocytes with roles in antimicrobial 
and antitumor immunity by killing target cells as their name implies (57, 58, 60). Activated NK 
cells lyse target cells via perforin and granzyme molecules upon recognition of changes in target 
cell membrane glycoproteins (58, 62). KC activate NK cell cytotoxicity by secreting IL-18. NK 
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cells can promote T cell immunity by recruiting T cells and producing IFN-γ (58). Also, NK 
cells can modulate the local immune response in the liver by balancing production of pro-
inflammatory and anti-inflammatory cytokines upon activation of their activating and/or 
inhibitory receptors (i.e. NK2GD) and Inhibition typically dominates over activation (57, 60).  
1.4.5 Hepatic Natural Killer T Cells 
1.4.5.1 NKT Cell Origin and Development 
NKT cells arise in the thymus and mature in peripheral tissues (60, 62, 80). NKT function in 
recognizing lipid antigens such as the glycolipid components of microbial cell walls (i.e. 
glycosphingolipid from Sphingomonas spp. and Diacylglycerol from Borrelia spp.) (58, 60, 81). 
In addition to exogenous lipid antigens, NKT cells can recognize endogenous glycolipids (82). 
Many cells in the liver can present glycolipid antigens to NKT cells via CD1d including 
hepatocytes, liver DC, SC, and KC (81, 83, 84).  
1.4.5.2 NKT Cell Frequency 
Natural Killer T (NKT) cells are highly enriched in mouse and human livers accounting for up to 
20% of liver lymphocytes in mice and up to 10% of liver lymphocytes in humans (57, 58, 62, 79, 
84, 85). NKT cells are far less abundant in the blood only found at a 0.5% frequency (62). NKT 
frequency is highly variable between mouse strains and humans (86). NKT cell numbers depend 
on chemokine and integrin interactions to localize to the liver similar to conventional T cells 
(86). 
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1.4.5.3 NKT Cell Phenotype 
NKT cells express markers characteristic of both NK cells and conventional T cells (57, 58, 81, 
84). Unlike conventional T cells, NKT cells have a restricted TCR repertoire and recognize 
antigen in the context of the MHC Class I like molecule CD1d (57, 58, 62, 79, 82). The 
invariable TCR is typically Vα14Vβ8 for mice and Vα24Vβ8 or Vα24Vβ11 for humans (62, 
82). 
CD1d-dependent NKT cells can by either type 1 invariant (CD4+) or type 2 subtypes 
(double negative), but type 1 invariant NKT cells greatly outnumber non-invariant type 2 NKT 
cells (57, 58, 79-81, 83). As expected, CD1d-dependent NKT cell numbers are drastically 
diminished in CD1d knockout mice (82). Moreover, the number and proportion of CD1d-
dependent NKT cells in the liver increases with age (80). Cd1d independent NKT cells are 
characterized as third non-classical subtype functioning to recognize other ligands outside of 
lipid antigens and their ontogeny is unclear (57, 82).  
1.4.5.4 NKT Cell Function 
NKT cells play an important role in innate and adaptive immunity since they can produce large 
amount of cytokines very rapidly (minutes) upon lipid antigen stimulation (60, 86). CD1d-
dependent and CD1d-independent NKT cells differ in their cytokine production (57). Most 
classical CD1d-dependent NKT cells are activated by IL-12 (from KC or DC) to perform 
perforin and Fas-mediated cell killing like NK cells (60, 84, 87). Moreover, CD1d-dependent 
NKT cells in the liver constitutively produce IFNγ (83). Generally, NKT cells are capable of 
producing pro-inflammatory (i.e. IFNγ, TNF-α) and anti-inflammatory (i.e. IL-4, IL-10, IL-13) 
cytokines when activated similar to NK cells (58, 62, 82). 
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1.4.5.5 The Good and the Bad 
NKT cells have overlapping function with NK cells in anti-microbial and anti-tumor defense (57, 
87). NKT cells have been implicated in a broad spectrum of diseases including cancer, Primary 
Biliary Cirrhosis, viral hepatitis, NASH, NAFLD, Type 1 Diabetes, allergy, allograft rejection, 
and GVHD (62, 79, 82, 84, 86, 88). Moreover, NKT cell activation in acute liver injury models 
(i.e. Concanavalin A, α-galactosylceramine, LPS) has demonstrated the hepatotoxicity potential 
of NKT cells (57, 62). However, NKT cells can also be hepatoprotective as demonstrated by 
liver injury models mediated by CCl4 and bile duct ligation (57). In addition, NKT cell 
deficiency can abrogate alcohol induced liver injury (57).  
1.4.5.6 Murine Model of Auto-immune Hepatitis 
The synthetic glycolipid α-galactosylceramide can specifically induce NKT cell activation in 
murine models in a fast and consistent manner (81, 88). Although  α-galactosylceramide is 
commonly used to induce an Autoimmune Hepatitis phenotype in mice, α-galactosylceramide 
injection does not cause hepatic inflammation in humans (57). Basically, α-galactosylceramide 
causes rapid reduction of NKT cells (apoptosis) followed by repopulation within a few days (80, 
81). The response is characterized by increased cytokine production (IFNγ and TNF-α) and 
concurrent liver damaged associated with increased liver enzymes ALT/AST (79, 81, 88, 89). 
Hepatic inflammation induced by α-galactosylceramide is a good model of AIH given the 
induction of autoantibody production (88). Mice of different background do exhibit differences 
in α-galactosylceramide susceptibility. For example, BL6 mice are high susceptible while 
BALB/c are characteristically resistant (81). The hepatic inflammation induced by α-





2.0  SPECIFIC AIMS 
The liver has several characteristics that distinguish it from other organs. Firstly, the liver 
receives approximately 80% of its afferent blood supply from the portal vein, the major draining 
tributary of the gastrointestinal organs. Secondly, Kupffer Cells and Liver Sinusoidal Endothelial 
Cells (LSEC) of hepatic sinusoids function primarily to scavenge components of the incoming 
portal blood. They are uniquely positioned to interact with circulating lymphocytes like Natural 
Killer T cells as well as gut-derived microbial products (MAMPs) (90). Consequently, KC (as 
well as other liver leukocytes) are strongly influenced by specific microbes (91-93). KC play 
essential roles in host defense and tolerance through their interaction with microbes as 
phagocytic cells (94) and interaction with lymphocytes as antigen presenting cells (APC) 
respectively (95).  While PAMP detection by specialized cells in the liver is critical for innate 
immunity and tolerance induction by liver leukocytes is undoubtedly characteristic of adaptive 
immunity, the location and distinctive characteristics of KC enable this cell type to functionally 
bridge these separate arms of the immune system. Surprisingly, few studies have explored the 
affects of the gut microbiome on liver tolerance although it is a major source of hepatic PAMPs. 
Therefore, we hypothesize that the gut microbiome contributes to the tolerogenic properties 
of the liver by 1) promoting the expansion and/or recruitment of KC that mediate tolerance 
or 2) modulating the tolerogenic properties of KC. We will test this hypothesis with the 
following aims: 
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Specific Aim 1: To identify Pattern Recognition Receptor (PRR) pathway(s) by which 
components of the gut microbiome utilize to interact with hepatic cells. PRR ligands (i.e. 
PDG and LPS) translocate from the gut lumen despite normal gut barrier function. Many NPC 
express PRR including KC and LSEC, however the culmination of effects resulting from PRR 
ligation on hepatic cells has been poorly characterized.  
Sub-aim 1A: To characterize the PRR pathway(s) influenced by gut-derived microbial 
products in the liver. PRR pathway activation by MAMPs most commonly leads to production 
of pro-inflammatory cytokines. However the liver is not constantly inflamed in spite of constant 
bombardment by gut-derived MAMPs (which presumably activate their PRR). We hypothesize 
that hepatic ‘conditioning’ by gut-derived microbial products contributes to the tolerant state of 
the liver. A comprehensive genomic study on hepatic PRR expression in the absence of gut flora 
has yet to be performed. Therefore, we plan to perform an affymetrix whole genome microarray 
study using mRNA isolated from the liver’s of mice +/- gut bacteria followed by comprehensive 
PRR pathway analysis.  
Sub-aim 1B: To characterize the PRR pathway(s) influenced by gut-derived microbial 
products in KC. Single PRR ligation on KC can induce expression of hundreds of genes. We 
hypothesize that the gut microbiome serves as a source of gut derived bacterial products with 
which KC interact via their PRRs leading to downstream alterations in gene expression that 
collectively make KC tolerogenic. Whole-liver microarray results will serve as a platform to 
analyze specific PRR expression patterns of KC isolated from mice +/- gut bacteria. The 
expression of genes resulting from PRR ligation on KC will be analyzed using RT-PCR, 
Immunofluorescence (IF), and Western Blot (WB) methodologies. 
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Specific Aim 2: To elucidate the effects of intestinal colonization on the growth of the KC 
population. Preliminary studies indicated that intestinal colonization by commensal microbes 
augments the number of hepatic leukocytes. However the underlying mechanisms are not clear. 
The following studies will further clarify the contribution of commensal bacteria to KC 
population development.  
Sub-aim 2A: To evaluate the relationship between gut microbiota density & KC population 
size. KC make up the largest population of tissue macrophage in the body. Our preliminary 
results indicate KC numbers are greater in adult mice with a stable gut microbiome in 
comparison to adult germ free (GF) mice (which lack a gut microbiota). We will further 
characterize the role of gut bacteria in KC population development by quantitatively evaluating 
KC population size during murine adolescence and in late adulthood using IF and Flow 
Cytometric (FC) methodologies in concert with bacterial load evaluation. 
Sub-aim 2B: To evaluate the relationship between gut microbiota density & KC progenitor 
frequency. As tissue macrophages, KC are part of the Mononuclear Phagocyte System (MPS) 
and populate the liver via monocyte recruitment and differentiation thereafter. Monocytes are 
derived from the bone marrow (BM) and can make up to 10% of the blood’s white cell count in 
humans. Clarke et al. has shown that the gut microbiome can influence BM-derived cells (28). 
To determine if the gut microbiome influences the frequency of KC progenitors, we will isolate 
PBMC from mice +/- gut bacteria to analyze monocyte frequency using FC.  
Sub-aim 2C: To evaluate the role of gut microbiota density in KC recruitment by LSEC. 
LSEC express many adhesion molecules to facilitate monocyte recruitment and differentiation 
into KC within the liver. Interestingly, the hepatic expression of Inter-Cellular Adhesion 
Molecule 1 (ICAM1) is reduced in mice lacking gut bacteria. To determine if LSEC facilitate 
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monocyte recruitment via up-regulation of ICAM1 in response to gut derived microbial products, 
we will track monocyte influx following KC depletion in mice +/- gut bacteria +/- ICAM1 
blockade. We will also track monocyte influx in ICAM1-/- mice following depletion of gut 
bacteria.     
Specific Aim 3: To elucidate the effects of intestinal colonization on the function and 
tolerogenic potential of KC. A previous study from our lab has shown that LPS exposure alters 
the maturity state and IL-6 production of liver DC. We suspect that microbial product exposure 
alters KC properties as well.  
Sub-aim 3A: To evaluate the relationship between gut microbiota density & KC phenotype 
and phagocytosis. KC are a heterogeneous population of tissue mφ. Periportal KC have been 
characterized as larger, more mature, and more phagocytic whereas centrilobular KC are smaller, 
less mature, and exhibit less phagocytic activity. We hypothesize, that in the absence of gut 
bacteria (elimination of gut derived microbial products in the hepatic sinusoids), KC 
heterogeneity and phagocytic function will be reduced. We will measure the expression of 
surface markers CD80, CD86, and MHC Class II to analyze KC maturation in mice +/- gut 
bacteria via FC. We will also evaluate KC phagocytic activity in periportal and centrilobular 
regions of the liver by injecting phagocytosable latex beads (micro-beads) into the tail vein. 
Sub-aim 3B: To evaluate the role of gut derived microbial products in KC tolerance. KC 
and their neighbors (LSEC) have the potential to release inflammatory cytokines (i.e. IL-6) in 
response to PRR ligation. However, KC also have the potential to release anti-inflammatory 
cytokines (i.e. IL-10) and/or reduce pro-inflammatory cytokine production in response to PRR 
ligation (termed KC tolerance). We suspect that ligation of multiple PRR by gut derived 
microbial products (either in sequence or simultaneously) results in KC tolerance. We plan to 
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assess the affects of the gut microbiota on KC in situ. To identify components of the gut 
microbiota that may condition KC to become tolerant, we will: 1) Isolate KC from mice +/- gut 
bacteria, 2) Stimulate KC with PRR ligands in vivo & 3) Measure cytokine production (IL-10 
and IL-6) resulting from PRR ligation using IF and IHC.   
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3.0  METHODS 
3.1 ANIMALS 
All mice received humane care according to the guidelines in the “Guide for the Care and Use of 
Laboratory Animals”. Germ Free (GF) and Conventional (CL) Swiss Webster (SW) male mice 
aged 3-4 weeks or 6-9 weeks were purchased from Taconic (New York) and the Center for 
Gastrointestinal Biology and Disease Core at the University of North Carolina (Chapel Hill). GF 
SW mice were maintained inside of a sterile vinyl isolator for 48 hours with sterilized food and 
water. CL SW mice were maintained under specific pathogen–free conditions according to the 
National Institutes of Health guidelines for the use and care of live animals. Antibiotics 
(Ampicillin 1g/L, Vancomycin 0.5g/L, Metronidazole 1g/L, and Neomycin 1g/L) were delivered 




3.2 CELL PREPARATIONS 
3.2.1 Non-Parenchymal Cells 
Livers were perfused with cold Hanks Balanced Salt Solution (HBSS) and digested with 2ml 
cold collagenase (1mg/ml) (Sigma Aldrich). Perfused livers were then excised following removal 
of the gallbladder and placed in a 1:1 solution of cold Phosphate Buffered Saline (PBS) 
(Invitrogen, San Diego, CA) and Complete Media (RPMI 1640, Sigma Aldrich, The Woodlands, 
TX) supplemented with 5% FBS, nonessential amino acids, sodium pyruvate, HEPES, L-
glutamine, 55µM ß-ME, and penicillin/streptomycin (Invitrogen). Excised livers were minced 
through a cell dissociation sieve (size 40, Sigma Aldrich) using a glass pestle for single cell 
suspension. The resulting cell suspension (50ml volume) was separated into hepatocytes (pellet) 
and NPC (supernatant) by centrifugation (500 rpm in off break setting for five minutes). The 
NPC fraction was passed through a 40µm cell strainer (BD Falcon, Franklin Lakes, NJ) and cell 
populations were stained for flow cytometry (FC). More than 85% of isolated NPC expressed 
common leukocyte antigen (CD45 AF700, Biolegend, San Diego, CA) as assessed by FC. 
  
3.2.2 Intra-hepatic Lymphocytes 
For intra-hepatic lymphocyte isolation, NPC were first separated from hepatocytes. Lymphocytes 
were separated from non-lymphocyte NPC, red blood cells, and debris using Lympholite M 
(Cedarlane, Burlington, NC) according to the manufacturer’s instructions.   
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3.2.3 Peripheral Blood Mononuclear Cells 
Peripheral Blood Mononuclear Cells (PBMCs) were obtained from systemic blood suspended in 
2ml HBSS for Ficoll (Invitrogen) gradient separation. The buffy coat was removed, washed, 
filtered (40µm cell strainer, BD Falcon, Franklin Lakes, NJ) and stained for FC. 
 
3.2.4 Bone Marrow 
Bone marrow was flushed using a 1:1 solution of PBS and Complete Media. Bone Marrow 




For systemic leukocyte analysis, 500µl systemic blood (heparinized) was obtained by cardiac 
puncture. Blood samples were analyzed by the Cell Counter (Beckman Coulter, Fullerton, CA).  
For ELISA assays, 500µl systemic blood was obtained by cardiac puncture and allowed to 
coagulate for 48 hours. Collected serum was used as directed to measure ALT (ALT ELISA, 
Novateinbio, Cambridge, MA) according to the manufacturer’s instructions. 
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3.3 FLOW CYTOMETRY 
Cells were resuspended in Facs Buffer (1% BSA, 0.1% Sodium Azide in PBS) and analyzed on 
an LSR II with Facs Diva software. FC data were analyzed with FlowJo using antibodies listed 
in Table 3.  
Antigen Clone Host Conjugate Source 
Flow Cytometry     
Gr1 (Ly6G) RB6-8C5 Rat PE eBioscience 
IgG2 Isotype control  Rat PE eBioscience 
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Table 3.  Cellular Staining Antibodies 
 
3.4 BACTERIAL DETECTION 
3.4.1 Stool Isolation 
The cecum was opened aseptically to collect stool samples. Total DNA was extracted from 80 
mg of cecal stool using a QIAmp DNA stool mini kit (Qiagen, Santa Clarita, CA) for bacterial 
F4/80  BM8 Rat PE-Cy7 eBioscience 
IgG2a k Isotype control  Rat PE-Cy7 Biolegend 
CD11b M1/70 Rat Pacific Blue Biolegend 
IgG2b k Isotype control  Rat Pacific Blue Biolegend 
MHC Class II (I-A/I-E)  M5/114.15.2 Rat Alexa Fluor 700 eBioscience 
IgG2b k Isotype control  Rat Alexa Fluor 700 eBioscience 
CD80 (B7-1) 16-10A1 Armenian Hamster PE eBioscience 
IgG Isotype Control  Armenian Hamster PE eBioscience 
CD86 (B7-2) GL1 Rat FITC eBioscience 
IgG2a k Isotype control  Rat FITC eBioscience 
Ly6C HK1.4 Rat PE Biolegend 
IgG2c k Isotype control  Rat PE Biolegend 
CD281 (TLR1) TR23 Rat PE eBioscience 
CD282 (TLR2) 6C2 Rat FITC eBioscience 
CD284 (TLR4/MD2 complex) MTS510 Rat PE eBioscience 
CD289 (TLR9) M9.D6 Rat FITC eBioscience 
TLR5 85B152.5 Mouse PE Imgenex 
CD16/CD32 (Fc Block) 93 Rat  eBioscience 
Tissue Staining     
F4/80 CI:A3-1 Rat   Serotec 
ICAM1 3E2 Hamster   BDPharmingen 
CD44 (LYVE1) ALY7 Rat  eBioscience 
Ki67 SP6 Rabbit  GeneTex 
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density assessment. Alternatively, fresh stool pellets were also collected for analysis of bacterial 
density variation over time and assessment of colonization dynamics. 
 
3.4.2 Bacterial Density Measurements 
Extracted DNA was submitted to real time PCR of the conserved region of the bacterial 16S 
rRNA gene using universal primers (Forward 5-TCCTACGGGAGGCAGCAGT-3 and Reverse 
5-GGACTACCAGGGTATCTAATCCTGTT-3) (96), calibrated using DNA from E. coli (max 
efficiency DH5α competent cells, Invitrogen). Amplification and detection of DNA by Q-PCR 
were performed with the 7500 Fast Real-Time PCR Instrument (Applied Biosystems, Foster 
City, CA). Bacteria enumeration used Invitrogen’s Bacteria Counting Kit.  
3.5 PRR LIGAND SCREENING 
Portal and Systemic Blood were collected from adult CL SW mice, plasma isolated and alkaline 
phosphatase activity was heat inactivated by 30 minute incubation at 56°C. PRR stimulation was 
tested by Invivogen (San Diego, CA) by assessing NF-κB activation in HEK293 cells expressing 
individual mouse PRR.  Briefly, Invivogen performed PRR ligand screening by assessing NF-κB 
activation in HEK293 cells expressing a single PRR. NF-κB activation was monitored by 
measuring secreted alkaline phosphatase, a reporter gene in HEK293 cells induced by NF-κB. 
Plasma from CL mice was tested on mouse NOD1, NOD2 and on mouse TLR-2, -3, -4, -5, and -
9. Plasma was tested in duplicate using a 1:10 dilution and compared to control ligands. The 
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following were used as positive controls: Heat-killed Listeria monocytogenes (HKLM) (TLR-2), 
Poly (I:C) (TLR-3), E. coli K12 LPS (TLR-4), S. typhimurium flagellin (TLR-5), CpG ODN 
1826 (TLR-9), C12-iEDAP (NOD-1), L18-MDP (NOD-2), and TNFα (NF-κB control cells). 
NF-κB Control cells (no PRR) and unstimulated PRR-expressing HEK293 cells were used as 
negative controls. The results are provided as mean OD values. For semi-quantification of 
ligands, plasma was concentrated 2-fold for testing (Amicon Ultra 3K Centrifugal Filters, 
Millipore, Marlborough, MA). Tenfold dilutions of plasma and positive control ligands were 
then tested in triplicate for activation of TLR-2, TLR-5, and TLR-9.  
3.6 PRR STIMULATION 
Flagellin (FLA-ST, Invivogen) (dose of 100ng, 100ul) was injected via tail vein into CL and GF 
mice. Controls were injected with 100µl PBS. NPC were isolated 24 hours post-challenge.  
3.7 TISSUE STAINING 
FFPE and OCT embedded tissue was sectioned (4 µm) and stained with antibodies listed (Table 
3). H&E staining was performed according to standard protocol. For Immunofluorescence, 
Qdot® Streptavidin conjugates (Invitrogen) were used following application of biotinylated rat 
secondary (BD pharmingen) or biotinylated hamster and rabbit secondary (Vector Laboratories, 
Burlingame, CA) antibodies.  Mirax Whole Slide Scanner created whole slide images for 
analysis (Zeiss, Thornwood, NY) using Axiovision Software. When comparing H&E sections 
 61 
between groups, histology scoring was performed blindly by two individual pathologists. 
3.8 PROTEIN EXPRESSION 
Protein was isolated from the left lateral lobe of CL, GF, and AVMN livers by tissue 
homogenization in RIPA buffer containing complete protease inhibitors (Roche, Indianapolis, 
IN). Protein quantification was assessed by BCA Protein Assay Kit (Pierce, Chicago, IL). 
Seventy-five micrograms of protein was run on SDS-PAGE.  Following electrotransfer to a 
nitrocellulose membrane, 5% milk in TBST (Tris buffered saline tween) was used for blocking. 
Monoclonal β-actin (clone AC-15, Sigma Aldrich), CD1d (clone Y17, Santa Cruz, Santa Cruz, 
CA), and ICAM1 (clone M19, Santa Cruz, Santa Cruz, CA) were used to probe the membrane. 
ECL western blotting substrate (Thermo Scientific, Ashville, NC) was used to visualize the 
protein.   
3.9 GENE EXPRESSION 
3.9.1 RNA Isolation, RT-PCR, and PCR for murine genes. 
Total RNA was extracted from homogenized liver tissue using Trizol (Invitrogen). Reverse 
transcription was performed using High Capacity RNA-to-cDNA Master Mix (Applied 
Biosystems) according to the manufacturer’s instructions. To determine expression of csf1 and 
csf2 relative to the hprt internal control, 25ng cDNA was used in a 10µl reaction using the 
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Taqman Fast Universal PCR Master Mix (Applied Biosystems) and Taqman array 96 well fast 
plates for Mouse Immune Response (Applied Biosystems). Analysis was performed on a 7500 
Fast Real-Time PCR Instrument (Applied Biosystems).  
 
3.9.2 Microarray 
Using the GeneChip Mouse Gene 1.0 ST Arrays from Affymetrix (Santa Clara, CA), we 
examined hepatic gene expression levels in CL, GF, and AVMN mice. Livers were collected 
from 18 mice (6 animals per experimental condition) and placed in Trizol (Invitrogen) for RNA 
extraction. Genome Explorations performed RNA extraction, labeling, and hybridization of 
cDNA onto gene chips (Memphis, TN) according to standard operating procedure. Gene signal 
values were calculated by RMA for background correction, normalization, and summarization. 
Differential Gene Expression was assessed using the following criteria: (1) Differentially 
expressed Genes (DEGs) had signal values ≥ 8 for all samples in one group, (2) False Discovery 
Rate (FDR)-corrected ANOVA p values were ≤ 0.05, (3) Absolute fold change was ≥ 1.5 and 
FDR corrected t-test p-values ≤ 0.05 with FDR correction performed by the Benjamini-Hochberg 
method (corrects type 1 error associated with multiple comparisons). Log 2 signal values for 
DEF probe sets were row mean centered and subjected to unsupervised hierarchal clustering by 
the complete linkage algorithm using Pearson Correlation as the similarity metric. Samples were 
clustered by Complete Linkage based on Pearson Correlation permitting identification of 
outliers. Results from the micro-array and pathway analysis were primarily performed by the 




Mice were injected (tail vein) with SpheroTM Carboxyl Magnetic Particles (1.22 µm) once 
(200µl, ~5.4 x 108 particles, Spherotech Inc., Libertyville, IL). NPC were isolated 24 hours later 
and active liver phagocytes were isolated by magnetic separation. Phagocytes were then counted 
and analyzed by FC.  
3.11 KUPFFER CELL REPOPULATION MODEL 
Kupffer Cells can be depleted using liposome entrapped clodronate (van Rooijen). CL mice were 
treated as described: Day 0: Clodronate Liposome injection (300µl, i.p.). Day 3: Blocking 
antibody injection i.p. using 50µg (100µl) anti-ICAM1 (YN1/1.7.4, Abcam) and/or 20 µg (100 
µl) anti-LYVE1 (CD44, IM7.8.1, Cedarlane, Burlington, NC). Rat IgG2b (50 µg, 100µl)  (BD 
Biosciences, San Jose, CA) was used as an isotype control. Day 6: KC Repopulation and 
Monocyte frequency assessment by FC.  
Cl2MDP (clodronate) was a gift from Roche Diagnostics GmbH, Mannheim, Germany. 
Other reagents to make liposome entrapped clodronate include: Phosphatidylcholine (LIPOID E 
PC) from Lipoid GmbH, Ludwigshafen, Germany; Cholesterol (SIGMA Chem.Co. USA); 
CL2MDP was synthesized by the laboratory of Dr. N. van Rooijen in Amsterdam, The 
Netherlands.  
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3.12 AUTOIMMUNE HEPATITIS MODEL 
Synthetic glycolipid antigens induce NKT cell mediated hepatitis modeling Autoimmune 
Hepatitis (81). CL SW and GF SW mice were treated as follows: α-Galactosylceramide 
(KRN7000, Funakoshi, Japan) was injected i.v. (tail vein) with a dose of 5μg (50μl). Controls 
were injected with 50 µl PBS. Blood and tissue were collected at 0, 12, and 24 hours post-
injection.   
3.13 STATISTICAL ANALYSIS 
The Student t test was used for statistical analysis of data when sample size was > four per 
group; the nonparametric Mann-Whitney U test was used when sample size was ≤ four per 
group. ANOVA was used when comparing more than 2 groups. Data are presented as the 
arithmetic mean. Error bars represent standard error of the mean. 
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4.0  RESULTS: KUPPFER CELL POPULATION DEVELOPMENT 
4.1 GUT BACTERIA ARE A MAJOR SOURCE OF SYSTEMIC MAMPS 
Gut bacteria shape normal gut morphology as evidenced by cecal dilation in GF and AVMN 
mice, which has been previously attributed to water and mucus accumulation and a thinner cecal 
muscularis propria (1, 4) (Figure 2).    
 
Figure 2. Gut Morphology. Top, representative images of intestines show cecal dilations in GF and AVMN, but 
not in CL mice (white arrow). Middle, representative images of the isolated cecum highlights dilation in GF and 
AVMN mice. Bottom, longitudinal H&E section of cecal wall shows thinned muscularis propria in the GF and 




Gut microbial density increases temporally and spatially with greatest bacterial loads 
found following weaning during adulthood and in the distal gut (4, 97) (Figure 3A and 3B). 
Bacterial density, however, varies with environment, mouse background, gender, and age (13, 
21). Since > 50% of gut bacteria cannot be cultivated (21, 25), we assessed cecal bacterial 
density via PCR amplification of the bacterial 16S ribosomal gene and via flow cytometry. Cecal 
bacterial density measurements showed that adult CL mice average > 12 million bacteria per 
gram of stool, but CL siblings housed in the same room, cage, and specific pathogen free 
conditions yielded a wide range of bacterial levels (Figure 3B). This variation is likely 
attributable to bacterial population dynamics. As expected, cecal bacteria were undetectable in 
GF mice (Figure 3A and 3B), whereas AVMN mice showed an 8.5-fold reduction in bacterial 
DNA relative to CL mice (Figure 3B, p=0.005).  
Live whole bacterial translocation to the liver rarely occurs under non-pathogenic 
homeostatic conditions (2, 23) (data not shown), but it is widely accepted that gut-derived 
MAMPs shed by commensals are able to penetrate the gut barrier. Yet, the amalgam of MAMPs 
able to translocate into portal and systemic circulation and to cause activation of TLR-expressing 
cells has not been fully characterized. It is also unclear whether physiologic levels of individual 
or combinations of MAMPs exert downstream effects on the liver. Therefore, we identified gut-
derived PRR ligands by screening portal and systemic blood for MAMPs using a NF-kB 
activation bioassay (Figure 3C). PRR ligation by MAMPs from portal and systemic blood was 
observed for TLR-2, TLR-5, and TLR-9, but not for TLR-3, TLR-4, NOD-1, or NOD-2 (Figure 
3C). Although TLR-4 and NOD ligands (LPS and PDG respectively) are known to be detectable 
in the portal circulation, their physiological concentrations may not be detectable in this bioassay 
or they might be in a form that does not trigger PRR signaling. Alternatively, LPS and PDG 
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might be responsible for the observed TLR-2 activation since both are known to bind to this 
receptor.   
We next examined NF-kB activation in response to TLR-2 (Figure 3D), TLR-5 (Figure 
3E), and TLR-9 (Figure 3F) ligation by portal blood MAMPs in comparison to concentrations of 
known TLR ligands (HKLM, flagellin, and CpG respectively). Figure 3E and 3F indicate TLR-5 
ligand concentration (presumably flagellin) ranges between 1-10ng/ml and TLR-9 ligand 
concentration (presumably bacterial DNA) ranges between 0.01-0.1 µg/ml in portal circulation. 
The relative concentration of TLR-2 ligand is indeterminate due to infidelity of TLR-2. 
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Figure 3. Gut Bacteria and Intestinal Permeability. (A) Bacterial DNA (ng) in 80mg cecal stool assed by real 
time PCR amplification of 16S rRNA gene in adolescent mice (3-4 weeks old) shows little difference in bacterial 
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load between GF and CL mice. (B) Left, bacterial density of cecal stool assessed by a Flow Cytometry Bacterial 
Counting Kit confirms the gut bacterial status of adult (6-8 weeks) CL and GF mice and shows the marked 
variability in CL mice. Right, bacterial DNA (ng) in cecal stool assessed by real time PCR amplification of 16S 
rRNA gene again shows absence (GF) or significant reduction (AVMN; ***p=0.005) and considerable variability of 
gut bacteria in CL mice (n=10). (C) Pattern Recognition Receptor (PRR) ligand detection in CL portal and systemic 
blood assessed by NFkB activation in HEK293 cells expressing mTLR2 (2), mTLR3 (3), mTLR4/CD14/MD2 (4), 
mTLR5 (5), mNOD1 (N1), mNOD2 (N2), or no PRR on NFkB Control Cells (C). Results represent blood pooled 
from 10 mice, averages are representative of two experiments performed in duplicate (Ŧ = activation levels above 
negative controls from the pooled sample of 10 mice; repeated twice). (D-F) Estimation of plasma TLR ligand 
concentrations for TLR2, TLR5, and TLR9 relative to known controls: (D) TLR 2 Activation on HEK293 cells by 
no ligand (Dashed line), Portal Blood (Solid line), HKLM (heat-killed Listeria monocytogenes (Dotted line) at 108, 
107, and 106. Blood pooled from 10 mice. Samples were run in triplicate. (E) TLR5 Activation on HEK293 cells by 
No ligand (Dashed line), Portal Blood (Solid line), Flagellin (Dotted Line) at 100, 10, and 1 ng/ml. (F) TLR9 
activation on HEK293 cells by No ligand (Dashed line), Portal Blood (Solid line), CpG ODN 1826 (Dotted Line) at 
1, 0.1, and 0.01 µg/ml. Conventional (CL), Germ Free (GF), and Antibiotic-Treated (AVMN) mice were used. 
4.2 KUPFFER CELL FREQUENCY AND MHC CLASS II EXPRESSION 
INCREASES WITH BACTERIAL DENSITY 
Ligation of a PRR (NOD1) by a gut-derived MAMP (PDG) results in expansion of specific 
mucosal immune cells (i.e. regulatory T cells) (69, 98). Since liver NPC, including KC and 
LSEC, express many PRRs for MAMP detection (40, 99), we determined whether gut bacteria 
stimulate expansion of liver immune cell populations. Results show nucleated sinusoidal cell 
number is reduced in GF livers (Figure 4, p=0.009). Similar results were obtained for the 
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absolute numbers of NPC isolated from CL and GF livers assessed by trypan blue exclusion of 
dead cells and cell counting (6.34 ± 1.2 million and 4.17 ± 1.2 million respectively, p=0.28).  
 
 
Figure 4. Sinusoidal Cells and Germ Status. Nucleated Hepatic Sinusoidal Cell Quantification; 10 High Power 
Fields (HPF, 40x) per region per group (n=3) of H&E sections were used to quantify sinusoidal cell count. Germ 
Free (GF) and Conventional (CL) mice were used. Statistical Significance indicated by: *P<0.05. 
 
Accordingly, we hypothesized that gut bacteria contribute to quantitative and/or 
qualitative characteristics of KC. First, we evaluated KC frequency during adolescence when the 
gut microbiome is not fully established.  During adolescence, CL mice have 15.2% F4/80+ NPC 
and GF mice have 17.11% F4/80+ NPC, though both CL and GF KC are relatively 
immature/inactivated as reflected by the insignificant MHC Class II expression (0.5% and 1.5 % 
F4/80+MHCII+ NPC respectively) (Figure 5A). However, the KC population size doubles 
during the transition from adolescence to young adulthood in CL mice whereas KC frequency in 
age-matched GF counterparts remains unchanged (CL 32% and GF 14% F4/80+ NPC in adults, 
Figure 5B).  Moreover, adult CL mice have a significant population of MHC Class II+ KC 
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(14.4% NPC) while adult GF mice (7.4% F4/80+MHCII+ NPC) resemble their juvenile 
counterparts (Figure 5B, Figure 6).    
Perplexed by the variability in CL KC compared to GF KC frequency, we hypothesized 
that the former might be related to the aforementioned differences in gut bacterial loads among 
CL mice (Figure 3B).  Results showed that gut bacterial load is directly related to the number of 
mature KC (F4/80+MHC II+ NPC) (Figure 5C, p=0.024). If more gut bacteria are associated 
with higher KC numbers, then less gut bacteria should result in lower KC numbers. As expected, 
AVMN mice showed a significant reduction in KC number compared to CL mice (AVMN 3.5% 
and CL 20.4% NPC) and either lose or fail to develop MHC Class II+ KC (AVMN 0.6% and 
CL13.5% NPC)  (Figure 5D).  
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Figure 5. The Gut Microbiota Increase Kupffer Cell Frequency. (A) Percentage of NPC isolated from livers of 
adolescent CL and GF mice expressing F4/80 (macrophage) or F4/80 and MHC Class II (mature macrophage) were 
similar. Representative of 3 independent experiments (CL n=6, GF n=6) (F4/80+ p=0.40 and F4/80+MHC II+; 
p=0.06). (B) Percentage of F4/80+ NPC (gray filled gate) or F4/80+MHC II+ NPC (black lined gate) isolated from 
livers of adult CL mice were significantly greater than GF mice (CL n=5, GF n=5; ***p<0.01). Dot Plots 
representative of 4 independent experiments. (C) Correlative analysis showed mature KC frequency (F4/80+MHC 
II+ NPC) was directly proportional to bacterial load (ng of bacterial DNA/g cecal stool); (Pearson’s correlation 
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coefficient=0.73; p=0.024). (D) Percentage of F4/80+ NPC (gray filled gate) or F4/80+MHC II+ NPC (black lined 
gate) isolated from livers of adult CL mice were significantly greater than AVMN mice (CL n=5, GF n=5; 
***p<0.01). Representative of 2 independent experiments. Adult Conventional (CL), Germ Free (GF), and 
Antibiotic-Treated (AVMN) mice were used. 
 
 
Figure 6. Kupffer Cell Numbers. Absolute KC Frequency in adult mice (Product of Absolute NPC count and 
average KC Percentage) (n=6), Representative of 3 independent experiments. Statistical Significance indicated by:  
*p<0.05. Conventional (CL) and Germ Free (GF) mice were used.  
 
Twice as many KC are located in periportal compared to the centrilobular sinusoids (94). 
We therefore determined if the KC deficiency observed in GF and AVMN mice was global or 
regional. CL mice exhibited twice as many KC in the periportal regions (40 KC/Hpf) compared 
to the centrilobular regions (18 KC/Hpf), but GF and AVMN mice exhibited both reduced 
periportal (22 KC/Hpf and 26 KC/Hpf) and centrilobular (13 KC/Hpf and 14 KC/Hpf) KC 
numbers respectively (Figure 7). The change in KC frequency could not be attributed to 
differences in liver size (Figure 8), lobular size (data not shown), or macrophage proliferation 
alone as assessed by Ki67 expression (Figure 9).  
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Figure 7. The Gut Microbiota Direct KC Distribution. KC distribution in livers of CL, GF, and AVMN mice 
assessed by immunofluorescence staining of liver sections with F4/80 (red) and DAPI (blue) nuclear counterstain. 
CL mice showed significantly more F4/80+ KC/HPF in both periportal and centrilobular sinusoids (**P<0.025; 
***p<0.01).  Representative images were selected from 3 liver sections per group consisting of 13-20 portal and 
central areas with vessel diameter between 50-200μm; Scale bar: 50μm. Adult Conventional (CL), Germ Free (GF), 






Figure 8. Liver and Body Size. Mean Liver (LM) and Body Mass (BM) shown. Adult Germ Free (GF, n=12), 
Conventional (CL, n=12), and Antibiotic Treated (AVMN, n=8) mice were used; BM (ANOVA p=0.029), LM 





Figure 9. Sinusoidal Cell Proliferation. Ki67 (green) indicates cell that has entered cell cycle. Representative 40X 
images shown from Conventional (CL), Germ Free (GF), and Antibiotic Treated (AVMN) mice; 15-20 images per 
region per group (n=3) used for quantification.  Although GF showed slightly less sinusoidal cell labeling, the 
differences were not statistically significant (ANOVA: portal p= 0.14 and central p=0.18). 
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4.3 GUT BACTERIA AFFECT KC PHENOTYPE AND FUNCTION 
KC can be divided into sub-populations based on inflammatory potential (inflammatory 
FSP1+F480+ cells and quiescent FSP1-F480+ cells) (77, 100). Therefore, we quantified the 
number of FSP1-positive and FSP1-negative KC in CL and GF mice to further characterize KC 
in the context of constitutive MAMP exposure. In absence of any supra-physiological 
stimulation, only a very small subset of F480+ cells also expressed FSP1 (1-2cells/hpf) and no 
differences in the number of FSP1+F480+ cells were observed between CL and GF mice (Figure 
10). Physiological levels of gut-derived MAMPs, therefore, were insufficient to elicit an 
inflammatory KC phenotype. This does not, however, exclude the possibility that FSP1 
expression by KC may change in response to acute or chronic supra-physiological stimulation.  
 
Fig 10. Kupffer Cell Inflammatory Potential. Inflammatory potential of Kupffer Cells (black) assessed by FSP1 
(dark pink) staining. Representative 40x images were selected from 2 liver sections per group consisting of 11-20 
portal and central areas with vessel diameter between 50-200 μm. Single FSP1+ Kupffer Cell is shown on far right 
at 100x. Left and Middle Scale bar: 50μm; Right Scale Bar: 20μm. Adult Conventional (CL) and Germ Free (GF) 
mice were used.  
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KC link innate and adaptive immunity by interacting with circulating lymphocytes in the 
hepatic sinusoid via MHC Class II presentation of antigenic epitopes following endocytosis of 
circulating antigens (74, 101). Loading of MHC molecules with antigenic peptide is often 
followed by up-regulation of co-stimulatory molecules CD80 and CD86. Because MHC Class II 
expression increased with higher bacterial loads (Figure 5B and 5D), we next assessed 
expression of co-stimulatory molecules CD80 and CD86 on KC and phagocytic function (part of 
exogenous pathway of antigen presentation). Results showed no significant differences in 
CD80/CD86 expression when comparing KC from CL, GF, and AVMN mice, although KC in 






Figure 11. KC Express Low Levels of Co-stimulatory Molecules. Co-stimulatory molecule expression (CD80 
and CD86) by KC from CL, GF, and AVMN mice showed no significant difference in percentage of F4/80+ NPC 
expressing CD80 (>90% for each group, p=0.50) or in percentage of F4/80+ NPC expressing CD86 (>20% for each 
group, p=0.17). Isotype controls are shown in gray. Histograms are representative of 2 independent experiments 
(n=5-6 per group). Adult Conventional (CL), Germ Free (GF), and Antibiotic-Treated (AVMN) mice were used. 
 
Since KC characteristically exhibit low levels of co-stimulatory molecules in comparison 
to other professional antigen presentation cells (90, 99), we assessed co-stimulatory molecule 
expression twenty-four hours after flagellin stimulation, which is the most highly detectable 
MAMP found in both portal and systemic blood (Figure 3C, 3E). Flagellin stimulation did not 
significantly increase or decrease co-stimulatory molecule expression by CL or GF KC (Figure 
12A). 
We next evaluated in vivo phagocytic activity by determining the number of active non-
endothelial phagocytes following magnetic isolation of cells containing micro-magnets (1.22 
µm). The percentage of active phagocytes was 5.4% (54,716 phagocytes/million NPC) in CL 
livers versus 9.7% (97,000 phagocytes/million NPC) in GF livers (Figure 12B). The increased 
phagocytic activity in GF mice suggests that MAMP exposure reduces environmental sampling 
although overall collective environmental sampling might be maintained in CL mice due to 
increased KC numbers.  
Because LPS has been shown to stimulate KC expansion (78), we determined if flagellin 
(the most highly detectable MAMP in portal circulation) generated a “CL phenotype” in GF 
livers (Figure 12C). Neither total KC (F4/80+ NPC) nor mature KC frequency (F4/80+MHC II+ 
NPC) were altered by flagellin stimulation at physiological concentrations within the limitations 
of a 24-hour time course to ensure no influence from environmental germ exposures in the GF 
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mice. However, KC progenitor (monocyte) frequency in GF livers nearly doubled that of CL 
livers post-challenge (Figure 12C). 
 
Figure 12. In vivo response to Antigenic Stimulation and Phagocytic Function.  (A) Co-stimulatory Molecule 
Expression on KC from CL and GF mice pre- (black solid line) and 24 hours post-treatment (black dashed line) with 
100ng of Flagellin (FLA) showed no significant difference; Isotype controls are shown in gray. Histograms are 
representative of 2 independent experiments (n=3-4 per group). (B) Phagocytosis (1.2 micron magnet uptake) assay 
shows that liver NPC from GF mice have significantly more phagocytic activity than CL mice (*p=0.031).  
Representative of 2 independent experiments (n=3 per group). (C) KC and Monocyte frequency in CL and GF mice 
pre- (0 hours) and post-treatment (24 hours later) with 100ng FLA shows FLA treatment does not cause significant 
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differences in KC frequency. However, the difference between CL and GF is obvious (***p<0.01). Monocyte 
Frequency (CD11b+Ly6C+ NPC) 24 hours post FLA challenge results in greater liver monocyte influx in GF mice 
compared to CL mice (***p<0.01). Representative of 2 independent experiments (n=3-4 per group). Adult 
Conventional (CL), Germ Free (GF), and Antibiotic-Treated (AVMN) mice were used.  
4.4 CONSTITUTIVE MAMP EXPOSURE DOES NOT CHANGE PRR EXPRESSION 
BY KUPFFER CELLS 
PRR are conserved germ-line encoded receptors (36, 99), but expression levels of some PRR (i.e. 
TLR-4) can increase in response to stimulation (40, 102). KC express many PRR constitutively 
(TLR-2, TLR-4, TLR-5, TLR-9 and NOD-2) (40, 48, 99), but we hypothesized that KC PRR 
expression might be dependent on constitutive MAMP exposure. Thus, TLR-2, TLR-4, TLR-5, 
and TLR-9 expression was evaluated before and after flagellin stimulation (Figure 13). Results 
show that CL KC and GF KC express surface TLR-2, TLR-4, TLR-5, and TLR-9 (Figure 13). 
TLR-5 expression was modestly increased in response to flagellin, but overall KC surface TLR 





Figure 13. Germ Status does Not Change Pattern Recognition Receptor Expression. TLR2, 4, 5, and 9 
expressions on KC (F4/80+ NPC) from CL and GF mice pre- (solid black line) or 24 hours post-treatment (dashed 
black line) with 100ng Flagellin showed no change in TLR expression. Isotype Controls are shown in gray. 
Histograms are representative of 2 independent experiments (n=3-4 per group). Adult Conventional (CL) and Germ 
Free (GF) mice were used.   
4.5 CLASSICAL KUPFFER CELL PROGENITOR FREQUENCY IS 
INDEPENDENT OF GUT BACTERIA  
KC arise from bone marrow-derived monocytes under the influence of colony-stimulating 
factors as defined by the mononuclear phagocyte system (MPS) (75, 94). Therefore, the KC 
deficiency associated with low gut bacteria could be due to: 1) deficiency of KC progenitors; 
and/or 2) failure of KC progenitors to differentiate. First, macrophage-colony stimulating factor 
(csf1) and granulocyte macrophage-colony stimulating factor (csf2), which drive monocyte 
differentiation and promote KC survival, were not differentially expressed (cDNA assessed by 
RT-PCR) between CL (average 2-∆Ct: csf1 0.16, csf2 0.009), AVMN (average 2-∆Ct: csf1 0.02, 
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csf2 0.01) and GF (average 2-∆Ct: csf1 0.62, csf2 0.0006) livers relative to the hprt1 internal 
control (Figure 14). Second, monocyte frequency (%CD11b+Ly6C+ or %CD11b+GR1+ cells) in 
the liver (<3% of NPC in CL, GF, and AVMN mice) (Figure 15A), circulation (CL 2.1 % 
PBMC, GF 3.4 % PBMC) (Figure 15B), and bone marrow (CL 51.3% BMDC, GF 53.4% 
BMDC) (Figure 15C) were unaffected by gut bacteria.  
Notably, however, a population of circulating CD11b-Ly6C+ cells was reduced in GF 
mice (Figure 15B). CD11b-Ly6C+ cells are not classically characterized as monocytes (myeloid 
lineage), but there is some plasticity within the MPS (75) and thus this cell population cannot be 
entirely excluded as precursors to KC or other cell types. Regardless, these findings indicate the 
frequency of intra-hepatic monocytes (classical KC progenitors) is independent of gut bacteria 
and the mobilization of monocytes from the bone marrow to circulation is not defective. 
Therefore, another mechanism is responsible for the KC deficiency associated with gut bacteria 
deficits.  
 
Figure 14. KC Differentiation Factor Expression in the Liver. Relative expression of M-CSF (csf1) (ANOVA 
p=0.50) and GM-CSF (csf2) (ANOVA p=0.84) showed no significant differences among the mouse groups. Black 
line represents mean expression, hprt used as internal control; CL (white circle) n=4, AVMN (gray circle) n=4, GF 




Figure 15. KC Progenitor Development is Independent of Gut Bacteria.  (A) KC progenitors in the livers of CL, 
GF, and AVMN mice showed no differences among groups (ANOVA p=0.663). Representative of 3 independent 
experiments (CL n=3-6, GF n=3-5, AVMN n=3-4). (B) KC progenitors in systemic circulation (% Peripheral Blood 
Mononuclear Cells (PBMC)) in CL and GF mice were not significantly different (p=0.27); CD11b+Ly6C+ PBMC 
(black lined gate). Circulating CD11b-Ly6C+ PBMC (black arrow; see text), however, were significantly lower in 
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GF mice; CL n=6, GF n=6 (***p<0.01). (C) KC progenitors in Bone Marrow (% Bone Marrow Derived Cells 
(BMDC)) in CL (n=6) and GF (n=6 mice) were not significantly different (p=0.37); CD11b+Ly6C+ BMDC (black 
lined gate). Conventional (CL), Germ Free (GF), and Antibiotic-Treated (AVMN) mice were used. 
4.6 MAMP EXPOSURE INDUCES ICAM1 AND LYVE1 EXPRESSION BY LSEC 
INCREASING KC RETENTION  
Monocyte recruitment to the liver in the infectious setting is stimulated by upregulation of 
adhesion molecules on LSEC (48, 103) although some adhesion molecules are thought to be 
constitutively expressed in the liver, including ICAM1 (70). Thus, we determined if basal 
adhesion molecule expression is modulated by MAMPs and if a change in adhesion molecule 
expression alters KC number. We first examined ICAM1 expression on LSEC (LYVE1+ cells), 
but LYVE1, a liver sinusoidal endothelial cell marker and adhesion molecule (103-105) was not 
consistently expressed between CL and GF mice (Figure 16A, Figure 17). Compared to 
expression in CL mice, quantitative morphometric examination of LYVE1 expression in GF 
livers was reduced (Figure 16A). ICAM1 expression was similarly reduced in GF livers, 
although particularly so in the centrilobular regions (Figure 16A, Figure 17). We confirmed by 
Western blotting that whole liver ICAM1 expression was significantly reduced in GF and 
AVMN mice (Figure 16B, p<0.001). 
A re-population model was next utilized to determine if LYVE1 and ICAM1 participate 
in shaping the KC profile under non-infectious conditions using a liposome-entrapped clodronate 
(CL2MDP) KC depletion protocol (Figure 15C). Monocyte influx and KC repopulation were 
tracked following ICAM1 or LYVE1 blockade. Neither ICAM1 nor LYVE1 blockade 
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completely significantly limited liver monocyte trafficking following KC depletion (Figure 
16D). However ICAM1, but not LYVE1, blockade did impede mature F4/80+MHC II+ KC 
repopulation (Figure 16E). ICAM1 blockade reduced monocyte influx by (53%, p=0.32) and KC 
population was stunted by (68%, p=0.04). LYVE1 blockade reduced monocyte influx by (80%, 
p=0.27) and KC population was stunted by (35%, p=0.41). Results indicate that monocyte 
recruitment is not dependent on ICAM1 alone, but full restoration of the mature KC population 




Figure 16. Constitutive ICAM1 Expression by LSEC is induced by the gut microbiota and Permits KC 
Repopulation. (A) ICAM-1 and LYVE1 protein expression in Liver; graphs illustrate quantification of 
immunofluorescence area per HPF that showed significantly higher ICAM1 and LYVE1 expression in CL mice (CL 
n=3, GF n=3; ***p<0.01). Five fields/region/mouse total 15 images per group used for analysis. (B) Western Blot 
showing higher hepatic ICAM-1 expression in CL mice compared to GF and AVMN mice (n=3) (ANOVA 
p<0.001). (C) Injection Scheme for Repopulation Model; Liposome entrapped Clodronate (CL2MDP) was used to 
deplete KC on Day 0; Either ICAM1 or LYVE1 blockade was performed on Day 3 following KC depletion; KC and 
monocyte frequency was assessed by Flow Cytometry on Day 6 post KC depletion. (D-E) Monocyte influx 
(CD11b+Ly6C+ NPC) in D; Untreated CL SW mice were used as negative controls (100% Influx). KC repopulation 
(F4/80+MHC Class II+ NPC) in E; Untreated CL SW mice were used as negative controls (100% Repopulation). 
Representative of 2 independent experiments (n=3-4 per group). Statistical Significance indicated by: *p<0.05 
experimental groups versus negative control, #p<0.05 experimental groups versus positive control. Conventional 





Figure 17. Tissue Expression of Adhesion Molecules in the Liver. ICAM-1 (red) and LYVE1 (green) expression 
on LSEC; DAPI (blue nuclear stain). Left most column, 10x representative overview image of liver section stained 
for ICAM-1; Second (MERGE), third (LYVE1) and fourth columns (ICAM-1) are 30x representative images of 
portal and central regions. Conventional (CL) and Germ Free (GF) mice were used. 
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5.0  RESULTS: INTRA-HEPATIC LYMPHOCYTE POPULATION DEVELOPMENT 
5.1 GUT BACTERIA STIMULATE EXPANSION OF INTRA-HEPATIC T 
LYMPHOCYTES 
T cells can be classified as conventional (CD4, CD8) T cells bearing T cell receptors that 
recognize MHC class I and MHC Class II restricted antigens as well as nonconventional T cells 
(NKT, γδ T) bearing nonconventional T cell receptors. Conventional CD4 T cells can be further 
classified as Th1, Th2, Th17, and regulatory T (Treg) based on cytokine production and function 
(106, 107). Despite the broad diversity and, at times, opposing functions of classes of T cells, gut 
bacteria module T cell numbers throughout the body (reviewed in (106)). Gut bacteria increase 
CD4 T cell numbers in the spleen (108) and peripheral lymph nodes (109), stimulate 
accumulation of CD4 Th17 cells in the colonic lamina propia (107), expand colonic Treg 
numbers (98), and boost distinct peritoneal γδ T cell numbers (106). Interestingly, the liver is 
particularly enriched in lymphocytes including both conventional and nonconventional T cells 
(58). Because the effects of the gut microbiota on T cell number appear to extend beyond the gut 
affecting immune organs (spleen), we hypothesized that liver lymphocytes would be secondarily 
affected by the gut microbiota since the liver is constantly filtering MAMP-laden blood traveling 
from the gut. Like previous studies in other organs, our results show a two-fold reduction in the 
percentage of intra-hepatic T cells (CD3+TCRβ+) found in GF livers (Figure 18A) compared to 
 89 
age-matched CL mice (4.24% NPC and 8.77%NPC respectively, p=0.005). In addition, the 
percentage of NKT cells (NK1.1+TCRβ+) was nearly depleted in GF livers (Figure 18A, 
p=0.007). As previously reported, the effect of the gut microbiota appears to predominantly 
affect T cells (108) and no differences were observed in percentages of intra-hepatic B Cells 
(5.18% NPC and 2.85% NPC, p=0.07) or NK Cells (1.67% NPC and 1.72% NPC, p=0.87), 
although intra-hepatic B cells appear to be mildly reduced in GF mice (Figure 18A).  
Inside the unique pool of conventional intra-hepatic T cells, the ratio of CD4 to CD8 T 
cells in the mammalian liver has been classically characterized as CD8 predominant (62, 110). 
However, the ratio of conventional intra-hepatic T cells differs among mouse species and is 
under the control of multiple intrinsic (genetic) and extrinsic (microbial) factors (111). 
Therefore, we further examined intra-hepatic T cells to determine the percentages of CD4 and 
CD8 T cells in CL and GF Swiss Webster mice. Results show that CD4 T cell predominate the 
intra-hepatic conventional T cell pool in both CL and GF mice, with a 2-fold reduction in 
percentage of CD4 T cells in GF mice and similar percentages of CD8 T cells between CL and 
GF mice (2.04% and 1.34% respectively, p=0.17) (Figure 18B). 
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Fig 18. Gut Bacteria modulate liver Non-Parenchymal Cell composition. (A-B) Non-parenchymal cells (NPC) 
were isolated from Conventional (CL) and Germ Free (GF) livers (CL n=6, GF n=6), data representative of one 
experiment. (A) Percentage of NPC that are T cells (CD3+TCRβ+) (p=0.005), NKT cells (NK1.1+TCRβ+) 
(p=0.007), NK cells (NK1.1+TCRβ-) (p=0.87), and B cells (Cd19+IgD+) (p=0.07). (B) Percentage of NPC that are 
CD4 T (CD4+TCRβ+) (p=0.005) cells and CD8 T (CD8+TCRβ+) (p=0.17) cells. Statistical Significance indicated 
by: ***P<0.01, **P<0.025, and *P<0.05. 
 
The murine NPC population is comprised not only of lymphocytes, but also of 
endothelial cells (40-50% NPC), stellate cells (10% NPC), and Kupffer Cells (20-30% NPC) (68, 
112, 113). The non-lymphocyte NPC greatly outnumber lymphocytes, therefore, to examine 
changes in intra-hepatic lymphocyte frequency induced by gut bacteria, we next examined 
absolute lymphocyte frequency. Results show greater lymphocyte numbers in CL adult murine 
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livers (415,000 ± 57,780) compared to GF adult murine livers (228,472 ± 35,329) (Figure 19A, 
p=0.009).  
Previous reports indicate conventional T and B lymphocytes comprise 43% of intra-
hepatic lymphocytes, and up to 65% of intra-hepatic lymphocytes are NK cells and 
unconventional T cells, which are found at much lower frequencies in circulation (114). 
However, T lymphocyte numbers vary in mouse strains and humans (86, 111). Results show that 
the proportion of CD4 T cells among intra-hepatic lymphocytes is significantly reduced in GF 
mice compared to CL mice (32.06% and 43.77% respectively) (Figure 19B). Similar proportions 
of CD8 T cells (13.35% and 13.67%), γδ T cells (10.09% and 9.95%), and NKT cells (6.22% 
and 5.46%) within the intra-hepatic lymphocyte population were observed in GF and CL mice 
(Figure 19B). However, considering the overall lymphocyte frequency is reduced, the absolute 
numbers of all T cell subsets were found to be reduced in GF mice (Figure 19C). Results show 
that GF mice have similar proportions of T cell subsets in the absence of gut bacteria compared 
to CL mice (Figure 19D), but that the overall intra-hepatic T cell population in GF mice is much 
smaller in comparison to CL mice and that the CD4 T cell population is particularly affected by 
the absence of germs compared to other T lymphocyte subsets examined in this study (Figure 
19C).   
In mice, T cells can be found in the hepatic sinusoids around the portal tracts and also 
distributed throughout the parenchyma (114). Reportedly, one third of intra-hepatic T cells 
express NK1.1 (115). Of those, 80% are CD4 NKT cells (iNKT) and the remaining 20% are 
reportedly double negative non-invariant NKT (79). Results show that NKT (NK1.1+CD3+), T 
(CD3+NK1.1-) and NK (CD3-NK1.1+) have similar distribution patterns in CL and GF livers 
(Figure 19E). No difference in NK cell number was observed between CL and GF livers in 
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accordance with previous data.       
 
Fig 19. Gut Bacteria modulate intra-hepatic T lymphocyte composition. (A-D) Lymphocytes were isolated from 
adult livers of adult Conventional (CL) and Germ Free (GF) mice. (CL n=6, GF n=6). Data representative of one 
experiment. A) Absolute count of liver lymphocytes in CL and GF mice. (B) Percentage of Lymphocytes expressing 
CD4 and TCRβ, CD8 and TCRβ, TCRγδ (NK1.1-TCRβ-), and NK1.1 and TCRβ. (C) Absolute counts of intra-
hepatic lymphocyte subsets: NKT (NK1.1+TCRβ+), Gamma Delta T (TCRγδ+NK1.1-TCRβ-), CD8 T (CD8+ 
TCRβ+), and CD4 T (CD4+ TCRβ+). (D) Relative proportions of intra-hepatic T lymphocytes (NKT, Gamma Delta 
T, CD8 T, and CD4 T). (E) Representative images of Immunohistochemical staining of CD3+NK1.1+ cells (black 
arrow) in the CL, GF, and AVMN (Antibiotic-treated) livers (3 sections per group). Statistical Significance 
indicated by: *P<0.05. 
 93 
5.2 BACTERIAL DEPLETION RESULTS IN INTRA-HEPATIC T LYMPHOCYTE 
REDUCTION 
The variability in human and murine intra-hepatic T cell numbers remains unexplained (115). 
We hypothesized that gut bacteria contribute to the accumulation of intra-hepatic T lymphocytes. 
We reasoned that if GF mice exhibit reduced intra-hepatic T lymphocyte numbers, then depletion 
of gut bacteria would yield a similar result. Results show that the intra-hepatic population of 
CD4 T cells in CL mice is approximately 40% while the intra-hepatic population of CD4 T cells 
in AVMN (antibiotic-treated) is reduced to 25% of lymphocytes (Figure 20A, p=0.041). The 
percentage of CD4 T cells (CD4+TCRβ+) that are also NKT (NK1.1+) cells is 60.8% and 43.2% 
in CL and AVMN mice respectively (Figure 20B). CD8 T cells were not significantly reduced by 
antibiotic treatment (27.9% CL and 15.1% AVMN) (Figure 20C). However, percentages of intra-
hepatic NKT cells were significantly reduced by antibiotic-treatment (CL 32.4% lymphocytes 
and AVMN 15.5% lymphocytes) (Figure 20D, p=0.043). Unlike GF mice, the absolute intra-
hepatic lymphocyte counts were not significantly different between CL and AVMN mice 
(385,000 ± 105,573 and 342,500 ± 84,125) (p=0.37) (Figure 20E).      
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Figure 20. Bacterial Depletion Decreases T lymphocyte Numbers. (A-E) Lymphocytes were isolated from adult 
livers of adult Conventional (CL) and AVMN (antibiotic-treated) mice, data representative of two independent 
experiments (CL n=3-6, AVMN n=3-5). (A) Percentage of Lymphocytes expressing CD4 and TCRβ. (B) Percentage 
of CD4+TCRβ+ Lymphocytes that also express NK1.1. (C) Percentage of Lymphocytes expressing CD8 and TCRβ. 
(D) Percentage of NK1.1+TCRβ+ Lymphocytes. (E) Absolute Lymphocyte Count for CL (n=5) and AVMN (n=5) 





5.3 NKT CELL MEDIATED LIVER INJURY INDUCED BY Α-
GALACTOSYLCERAMIDE IS ABROGATED IN GERM FREE MICE 
Conventional T cells (CD4 and CD8) recognize antigens via TCR and MHC (Class II and Class 
I) interactions respectively. NKT cells, bearing TCR with an invariant TCRα chain and restricted 
TCRβ chain, recognize exogenous and endogenous glycolipid antigens presented by the MHC 
class I like molecule CD1d (80). CD1d-restricted NKT cells can be activated directly by 
bacterial glycolipids derived from Sphingomonas spp., Borrelia burgdorferi, Leishmania 
donovani, and Entamoeba histolytica (116, 117). Moreover, the synthetic glycolipid α-
galactosylceramide can activate NKT cells in a fast and selective manner, resulting in non-
Kupffer Cell dependent liver injury that resembles acute autoimmune hepatitis (81, 88). 
Accordingly, the effect of gut bacteria on intra-hepatic NKT cell development would likely be 
discerned employing the α-galactosylceramide model of liver injury (Figure 21A). Therefore, we 
hypothesized that germ free mice, containing fewer intra-hepatic NKT cells, would exhibit either 
mild or absent hepatitis in response to α-galactosylceramide stimulation. Histology results 
illustrate the degree of liver injury mediated by α-galactosylceramide in CL and GF mice in just 
24 hours compared to untreated controls (Figure 21B). Blinded histological scoring of liver 
tissue isolated from α-galactosylceramide-treated CL and GF mice revealed inflammation was 
greatest in periportal regions of CL livers and that α-galactosylceramide treatment had a more 
significant effect on CL livers (Figure 21C, periportal p=0.008, centrilobular p=0.007). 
Moreover, the frequency of hepatocyte apoptosis (CL, 2.46 apoptotic foci/hpf and GF, 1.13 
apoptotic foci/hpf, p=0.01) was greater in CL livers following α-galactosylceramide treatment 
(Figure 21D). The degree of liver injury was also assessed by measuring serum ALT (Figure 
21E). Concordant with liver histology, the serum ALT level was significantly greater in CL α-
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galactosylceramide treated mice in comparison to GF α-galactosylceramide treated mice 12 
hours after treatment (Figure 21E). 
 
 
Figure 21. αGalactosylceramide induces NKT cell mediated inflammation.  (A-E) Conventional (CL) and Germ 
Free (GF) mice were used in a NKT cell mediated-hepatitis model, data representative of one experiment. A) 
Injection Scheme for NKT cell-mediated hepatitis model; KRN7000 (5μg, 50μl) or PBS was injected (tail vein) into 
CL and GF mice on Hour 0. Blood and tissue was collected at 0, 12, and 24 hours post-injection. (B) Representative 
H&E images from CL and GF livers (n=6 per group) at 24 hours post-injection of KRN7000, 20x Magnification. 
(C) Blinded Inflammatory scores of H&E images from periportal (p=0.008) and centrilobular (p=0.007) regions of 
CL and GF livers (6 sections per group) at 24 hours post-injection of KRN7000 (D) Apoptosis (apoptotic 
bodies/hpf, p=0.01) at 24 hours post-injection of KRN7000 (n=6 per group). (E) Serum ALT measured by ELISA at 
0, 12, and 24 hours post-injection of KRN7000. Conventional (CL) and Antibiotic-Treated (AVMN) mice were 
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used. GF ALT is significantly lower (P=0.04) at 12 hours post-treatment. Statistical Significance indicated by: 
***P<0.01,**P<0.025, *P<0.05. 
5.4 GUT BACTERIA DO NOT AFFECT CIRCULATING LYMPHOCYTES, BUT 
INFLUENCE LYMPHOCYTE ADHESION AND ACCUMULATION IN THE LIVER 
Lymphocyte recruitment to the liver differs from other organs, with Intercellular adhesion 
molecule-1 (ICAM1), vascular cell adhesion molecule-1 (VAP1), and CD44 expressed by LSEC 
facilitating lymphocyte adhesion and accumulation in the liver instead of leukocyte rolling 
mediated by selectins as seen in peripheral organs (63, 64). In fact, the number of times that 
blood circulates through the liver (360 times/day) and the slow rate at which blood flows through 
the narrow sinusoidal vasculature (25-250 μm/min) promotes contact between circulating 
lymphocytes and the LSEC (118). Moreover, the number of active binding sites on LSEC is 
critical for lymphocyte accumulation in the liver (63, 118). We investigated whether gut bacteria 
affect 1) circulating lymphocyte number or 2) expression of adhesion molecules by LSEC. 
Results show that neither circulating white blood cell counts (Figure 22A, p=0.09) nor 
circulating lymphocyte numbers (Figure 22B, p=0.12) were affected by gut bacteria.  
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Figure 22 Gut Bacteria do not affect circulating lymphocyte numbers. (A-B) CBC with Differential was 
performed on systemic blood from Conventional (CL) and Germ Free (GF) mice, data representative of two 
independent experiments.(A) White Blood Cell (WBC) counts from CL (n=6-8) and GF (n=5-6) mice. (B) 
Circulating Lymphocyte counts from CL (n=6) and GF (n=5) mice. Statistical Significance indicated by: *P<0.05. 
 
ICAM1 knockout mice characteristically have increased numbers of circulating 
leukocytes (119). Also, gut bacteria regulate ICAM1 expression in many organs (stomach, 
spleen, liver, intestines, kidney, skin, and skeletal muscle) (70). As shown previously, we saw 
reduced intra-hepatic T cell frequency in GF mice concomitant with reduced ICAM1 and CD44 
expression by LSEC, molecules required for T cell accumulation in the liver. Results show that 
both CD44 and ICAM1 expression in GF livers is significantly reduced in comparison to CL 
counterparts (Figure 23A).  
Finally, while circulating lymphocyte-LSEC adhesion contributes to the overall 
accumulation of intra-hepatic T cells, the development of intra-hepatic NKT cells has an 
additional level of complexity.  NKT precursor cells form in the thymus at the neonatal stage and 
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migrate predominantly to the liver where they mature with less migration to sites such as the 
bone marrow and spleen (80, 88, 120). Both type I and II NKT (invariant TCR and non-invariant 
TCR) require CD1d for development in the mouse as demonstrated by CD1d knockout studies 
where these cells are absent (27, 57, 86). CD1d expression is particularly omnipresent in the liver 
as its expression is found on antigen presenting cells like macrophages, Dendritic Cells, and B 
cells, but also hepatocytes (121, 122). Moreover, CD1d expression levels increase during 
bacterial infection (116) and MHC class II expression by Kupffer Cells is decreased in absence 
of gut bacteria (manuscript in submission).  Thus, we hypothesized that CD1d expression would 
be reduced in the livers of GF mice given lower microbial stimulation. Results show reduced 




Fig 23. Gut Bacteria induce hepatic CD1d expression. (A) ICAM (yellow) expression and CD44 (red) expression 
by LSEC (B) Western Blot showing hepatic CD1d (37kDa) in CL, GF, and AVMN mice (n=3 per group). 
Conventional (CL), Germ Free (GF) and Antibiotic-Treated (AVMN) mice were used. 
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6.0  RESULTS: THE GUT MICROBIOTA REGULATES THE HEPATIC GENE 
EXPRESSION PROFILE 
The liver is the metabolic center, functioning as a sensor and effector in the metabolism of fat, 
sugars, proteins, and xenobiotics (123, 124). In carbohydrate metabolism, absorbed glucose is 
taken up by the liver and consumed by the intestine, pancreas and spleen (123). Insulin 
dependent organs include skeletal muscle, heart and adipose tissue while the insulin independent 
organs include CNS and blood erythrocytes, which all require glucose. In the fasting state or 
during exercise, the liver meets the body’s glucose demands via glycogenolysis (breakdown of 
glycogen) or gluconeogenesis (synthesis of glucose from stored substrates).  In fat metabolism, 
absorbed dietary fat is stored in adipose tissue and liberated fatty acids are converted to 
triglycerides by the liver for release into VLDL. In nitrogen metabolism, ammonia is produced 
and the urea cycle exclusively occurs in the liver. In addition, the liver functions in conversion of 
xenobiotics and formation of bile acids.  
Because hepatic cellular composition as well as non-parenchymal cell function was 
affected by the gut microbiota, the gut microbiota aid in host metabolism by metabolizing 
otherwise indigestible dietary components, the gut microbiota have been shown to alter the 
systemic metabolic profile, and the significant weight difference observed between GF and CL 
mice (Figure 8), we hypothesized that the hepatic metabolic profile would differ between GF, 
AVMN, and CL mice.  
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Total hepatic gene expression is dependent on gut bacteria as evident by the grouping of 
individual CL, GF, and AVMN livers together with livers from the same experimental conditions 
(Figure 25 and 26). The discrimination between CL and GF livers is smaller than the 
discrimination between CL and AVMN or GF and AVMN livers (Figure 26), which indicates 
that antibiotics may also affect gene expression in addition to germ status.  
The microarray revealed 163 differentially expressed genes grouped into five clusters 
based on gene relatedness. The genes within these clusters fell into the following categories: 
Retinol metabolism (13), Metabolic pathways (53), Biosynthesis of unsaturated fatty acids (8), 
Circadian rhythm (5), Linoleic acid metabolism (7), Steroid biosynthesis (5), PPAR signaling 
pathway (9), Arachadonic acid metabolism (9), Amino sugar and nucleotide sugar metabolism 
(7), Metabolism of xenobiotics by cytochrome P450 (7), Drug metabolism by enzymes (6), 
Primary bile acid biosynthesis (4), Complement and Coagulation cascades (7), Alanine 
metabolism (4x), Fatty acid metabolism (5), Androgen and estrogen metabolism (4), Prion 
diseases (4), Terpenoid backbone synthesis (2), Sulfur metabolism (2), Regulation of autophagy 
(3), Butanoate metabolism (3), Fructose and mannose metabolism (3), and limonene and pinene 
degradation (2) (Figure 26).  These data suggest that genes involved in metabolism are the most 
differentially regulated.  
Of the differentially expressed genes (DEGs) identified, our findings support the 
influence of commensals in the synthesis of unsaturated fatty acids, linoleic acid metabolism, 
steroid metabolism, metabolism of arachadonic acid, metabolism of xenobiotics by cytochrome 
P450, and bile acid synthesis (124, 125). The influence of gut bacteria on the following members 
of the cytochrome P450 family has been previously reported: Cyp1a2, Cyp2a4, Cyp2b9, 
Cyp2b13, Cyp2c37, Cyp3a11, Cyp3a13, Cyp3a16, Cyp3a25, Cyp3a41, and Cyp3a44 (125). We 
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found that the expression of Cyp2a22, Cyp2b10, Cyp2b9, Cyp2c37, Cyp2c50, Cyp2c54, 
Cyp2c55, Cyp4a10, Cyp4a14, Cyp4a31, Cyp4a32, and Cyp26a1 was higher in GF mice 
compared to CL counterparts, while expression of Cyp2c39, Cyp3j9, Cyp3a11, Cyp3a41a, 
Cyp3a44, and Cyp7b1 was lower in GF mice compared to CL counterparts.  
The role of gut bacteria in the entero-hepatic cycle of bile is well characterized. Gut 
bacteria enable recycling of bile acids via transformation of primary bile acids (cholic acid and 
chenodeoxycholic acid) into secondary bile salts (lithocholic acid and deoxycholic acid) (124), 
therefore the implicated role of gut bacteria in bile synthesis in our study was unsurprising. 
Regarding fat metabolism, Fiaf (angiopoietin-like protein 4) is a prominent mediator of 
fat storage and energy expenditure via β-oxidation (124). Accordingly, we found that Fiaf was 
down regulated in GF and AVMN mice compared to CL counterparts, likely due to reduced fat 
uptake from the gut. Other notable differentially regulated genes involved in fat metabolism 
include fatty acid synthase and lanosterol synthase (both down-regulated in GF and AVMN 




Figure 24. Principle Components Analysis. PCA shows obvious discrimination between GF 
(yellow) and CL (blue) livers.   
 
Figure 25. Principle Components Analysis. PCA shows greater discrimination of AVMN 
(purple) livers as a group relative to GF (yellow) and CL (blue) livers. Sample C from the 




Figure 26. Heat Map of Differentially Expressed Genes. Clusters A-E correspond to DEG 
similarity. 
 
In light of our previous findings that leukocyte frequency (KC and T lymphocyte) was 
drastically diminished in absence of gut bacteria, we expected to observe corresponding changes 
in the hepatic gene profile of GF and AVMN mice. Reikvam et al. performed a similar study 
comparing gene expression in the intestines of CL, GF, and antibiotic-treated mice revealing 517 
DEGs belonging to the following categories: cell cycle, lipid biosynthesis, inflammatory 
response, apoptosis, DNA damage response, and oxidative stress regulation (126). Five genes 
encoding antimicrobial factors were identified in their study (Reikvam).  Likewise, we identified 
28 DEGs involved in different aspects of immunity (Table 4 and 5).  
As previously mentioned, PRR signaling pathways coalesce at the level of transcription 
factor activation and transcription of genes or post-translational modification, ultimately leading 
to the production of inflammatory cytokines and antimicrobial molecules. Cytosolic RLRs 
induce raet1e upon activation (Table 4). Both cytoplasmic and transmembrane PRR activate 
IRFs including IRF2 (Table 4). Viral MAMP recognition induces the production of Type 1 
interferons like IFNα5, whose expression is reduced in CL and AVMN livers (Table 4). 
Moreover, all TLR utilize kinases to transduce signal activation (i.e. MAP2K) (Table 4). The 
pro-inflammatory cytokine production in response to PRR activation often includes IL-1 (i.e. 
NOD1/2) and IL-6 production (i.e. TLR4) whose affects are exerted by binding to respective 
receptors IL-1R and IL-6R (Table 4), both of which are expressed at a lower level in GF livers in 
comparison to CL counterparts. In addition, IL-22 production can be inflammatory or anti-
inflammatory depending on the cytokine microenvironment and its receptor is found to 
expressed at a lower level in GF livers as well (Table 4). Lastly, TLR-4 signaling is dependent 
on TLR-4-MD2-CD14-LPS complex formation unlike the other TLR, which simply bind their 
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cognate ligands irrespective of adaptor molecules. While TLR 4 is a transmembrane PRR, the 
MD2 adaptor protein is secreted by the liver and loosely associates with the extra-cellular 
domain of TLR4 (74). MD2 (Ly96) expression is also lower in GF livers reflective of the lack of 
LPS stimulation.  
Several genes related to immune cell phenotype, differentiation, apoptosis, and 
proliferation were differentially regulated (Table 4 and Table 5). However, the implications of 
such changes in gene expression are unclear. The increases in lymphocyte 6 Antigen Complex 
genes are likely compensatory in response to lack of immunostimulation from gut bacteria. 
However, the decreased expression of genes involved in both proliferation (LIFR) and apoptosis 
(TRAIL) in GF livers is paradoxical (Table 5).  
Interestingly, three genes involved in antigen presentation and processing had reduced 
expression in GF livers. We previously showed a lack of MHC Class II expression on KC in GF 
mice as well as AVMN mice (Figure 5). Although, KC are not the only MHC class II expressing 
NPC in the liver, professional antigen presenting cells characteristically possess all machinery 
for antigen presentation in this pathway including proteolytic enzymes for the endocytosis and 
degradation of antigens to be loaded onto the MHC Class II molecules. Cathepsins are involved 
in antigen processing and loading (127), two of which have reduced expression in GF livers 
(Table 5). Moreover, the expression of the invariant component of the actual MHC Class II 
molecule was reduced in GF mice as well (Table 5) (38). 
The liver synthesized most of the plasma components of blood (i.e. albumin). An 
important component of systemic innate immunity includes circulating complement proteins and 
acute phase reactants, which are also produced by the liver (62). The complement system 
consists of over 30 proteins (57), both stimulatory and inhibitory in nature. Results show that 
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Hemolytic Complement, Complement component 2, Complement component 6, and 
Complement component 9 all had reduced expression in GF livers. Additionally, regulatory 
components of the complement cascade (Decay Accelerating Factor and Complement 
component Factor I) exhibited reduced expression as well.  
Unfortunately, the microarray data did not yield any inkling about cell deficiency 
resulting from bacteria deficiency. The raw data of the microarray was extensively checked for 
even subtle differences in the expression of leukocyte specific chemokines, cytokines, and CD 
(cluster of differentiation) markers. Moreover, because the microarray did not yield a discernable 
difference in ICAM1 expression (although two methods of protein expression confirmed a 
difference in ICAM1 protein expression) between CL and AVMN or CL and GF mice, we 
reasoned that differential expression of genes of interest might be confirmed using classical PCR. 
No differences in mRNA expression of leukocyte specific CD molecules (i.e. CD19 for B cells) 














Table 4.  Immunity-related DEGs I 
DEG AVMN/CL GF/CL AVMN/GF Pathway 
 Log2 Signal Difference  
Raet1e 
Retinoic Acid Early Transcript delta 
0.13 -1.35 1.47 PRR Signaling 
IRF2 
Interferon Regulatory Factor 2 
0.36 0.71 -0.36 PRR Signaling 
IFNα5 
Interferon α5 
-0.65 -0.5 -0.60 PRR Signaling 
MAP2k  
Mitogen activated protein kinase 
0.69 0.25 0.44 PRR signaling 
Ly96 
Lymphocyte Antigen 96 also called MD2 
0.62 -0.29 0.90 PRR Signaling 
IL22R 
Interleukin 22 Receptor 
0.03 -0.65 0.68 PRR signaling 
 
IL1R 
Interleukin 1 Receptor 
0.03 -0.16 1.99 PRR signaling 
IL6R 
Interleukin 6 Receptor 
0.21 -0.62 0.83 PRR Signaling 
MIF 
Macrophage Migration Inhibitory Factor 
0.42 -0.21 0.63 PRR signaling 
Ly6C2 
Lymphocyte Antigen 6 Complex, Locus C2 
0.17 0.72 -0.56 Immune Cell 
Ly6A 
Lymphocyte Antigen 6 Complex, Locus A 
0.51 2.44 -1.92 Immune Cell 
Ly6C1 
Lymphocyte Antigen 6 Complex, Locus C1 
0.28 1.24 -0.86 Immune Cell 
LY6F 
Lymphocyte Antigen 6 Complex, Locus F 
-0.09 0.64 -0.76 Immune Cell 
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Table 5.  Immunity-related DEGs II 
DEG AVMN/CL GF/CL AVMN/GF Pathway 
 Log2 Signal Difference  
IL11R 
Interleukin 11 Receptor 
-0.19 0.44 -0.63 Natural Killer Cell 
Differentiation 
LIFR  
Leukemia Inhibitory Factor Receptor 




1.40 -0.99 2.39 Immune Response 
Apoptosis 
Factor XI 
Coagulation Factor 11 
0.63 0.10 0.53 Blood coagulation 
Metallothionein 1 -1.03 -2.90 1.88 Acute Phase Response 
Metallothionein 2 -1.02 -1.86 0.84 Acute Phase Response 
Hc 
Hemolytic Complement 
-0.18 -0.81 0.62 Acute Phase Response 
Immune Response 
CfI 
Complement Component Factor I) 
0.11 -0.75 0.86 Acute Phase Response 
Immune Response 
DAF  
Decay Accelerating Factor  
0.23 -0.45 0.67 Acute Phase Response 
Immune Response 
C2 
Complement Component 2 
0.43 -0.33 0.76 Acute Phase Response 
Immune Response 
C6 
Complement Component 6 (MAC) 
0.11 -1.21 1.32 Acute Phase Response 
Immune Response 
C9 
Complement Component 9 (MAC) 
-0.04 -0.61 0.57 Acute Phase Response 
Immune Response 
Cathepsin E -0.22 -2.46 2.24 Antigen Processing 
Cathepsin Z 0.27 -0.47 0.73 Antigen Processing 
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CD74  
Invariant Polypeptide of MHC Class II 
0.51 -0.53 1.04 Antigen Presentation 
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7.0  DISCUSSION 
7.1 GUT BACTERIA AND KUPFFER CELL DEVELOPMENT 
Uniqueness of the liver as an immunologic organ resides, in large part, in the enrichment of 
specialized leukocyte subsets that are not found at the same concentrations in other organs (60) 
and the highest concentration of tissue macrophages (KC). Our results show that constitutive 
exposure to MAMPs via portal blood shapes the sentinel KC population for sinusoidal content 
monitoring, which in turn, can trigger various innate and adaptive immune responses. These 
include clearance of bacteria, phagocytosis of malignant cells, platelet aggregates, activated 
complement components, and antigen presentation to T cells/activation and T cell tolerance (74, 
128).  
Leukocyte populations in the gastrointestinal tract are largely shaped by luminal gut 
bacteria (129).  Permanent residence and close proximity of bacteria to tissue evolved into a 
symbiotic and carefully balanced relationship referred to by some as “physiologic inflammation” 
(129), whereby local immunity is “primed” for reactivity and protection from pathogens, but 
without commensal bacteria-triggered auto-aggressive tissue damage. 
In the liver, we observed germ line KC PRR expression, regardless of gut bacteria, but 
MAMP exposure triggers hepatic KC recruitment maturation/activation characterized by 
increased MHC Class II+ KC and decreased phagocytic activity. Co-stimulatory molecule 
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expression, however, remains low in both CL and GF KC.  MAMPs, therefore, help shape the 
relatively ‘tolerogenic’ KC phenotypic profile that contributes to inefficient antigenic 
presentation to T cell along with KC secretion of IL-10 and TGFβ (60, 90, 130). 
Previous studies show that mono-association of GF mice with Lactobacillus delbrueckii 
(131), inoculation of GF rodents with Saccharomyces cerevisiae (93), and mono-association of 
GF rats with Escherichia coli (78) all lead to increased KC numbers. Komatsu et al. previously 
showed dynamic regulation of liver endothelial ICAM1 expression by gut bacteria (70). 
Increased LSEC ICAM1 expression has been associated with monocyte/macrophage recruitment 
during bacterial infection (103) and KC expansion in old age (132). We have confirmed, linked, 
and furthered these previous observations by showing that under physiological conditions gut 
bacteria: 1) release specific cocktail of MAMPs into circulation, which upregulate LSEC ICAM1 
expression, and are largely responsible for “constitutive expression”; 2) density is directly 
proportional to KC numbers, phagocytic function, and MHC Class II expression; and 3) density 
fluctuations occur naturally or can be induced via broad spectrum antibiotic treatment.  
KC comprise more than a third of total liver NPC (73) and participate in many critical 
processes, sometimes playing a protective role and other times a deleterious one depending on 
context.  They have been implicated in: liver fibrosis as activators of hepatic stellate cells; 
mediators of inflammation and ischemia/reperfusion injury; adverse drug reactions; metastatic 
tumor cell clearance; liver tolerance induction; liver regeneration; and bacteria/virus clearance 
(73, 74, 90, 101, 130). By extension, therefore, gut bacteria can directly and indirectly influence 
many aspects of liver pathobiology.   
We observed that development of KC and liver immunity is directly influenced by gut 
bacteria on a sliding scale: more gut bacteria, more circulating MAMPs, more LSEC 
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activation/ICAM1 expression, more monocyte adhesion, and finally more KC.  Our results are 
consistent with established clinical observation that selective bowel decontamination before liver 
transplantation significantly increases the risk of infections, whereas as pre- and probiotic 
treatment shows an opposite trend (133).   
It is not unreasonable to speculate that defects in liver immunity or bacterial/MAMP 
dysbiosis might also contribute to susceptibility, progression, or skewing of other liver diseases 
as has been shown for the intestine and for allergic reactions (134). This study focused on gut 
bacterial density, but many other aspects of this intricate system, such as changes in bacterial 
species and relative proportions, are likely to be fruitful areas for further investigation. 
7.2 GUT BACTERIA AND INTRA-HEPATIC LYMPHOCYTES 
From person to person, the relative frequencies of intra-hepatic T cell subsets can vary 
considerably. The variation among individuals is likely reflective of antigenic exposure as much 
as genetic background (114). However, given the emerging role of gut bacteria in the 
development of both mucosal and systemic immunity and their role in Kupffer Cell 
development, it would not be surprising for gut bacteria to shape the intra-hepatic T cell 
repertoire. Yet, the impact of the gut bacteria on T cell development has primarily been 
characterized outside of the liver.   
Katz et al. demonstrated that the liver is enriched in nonconventional T cells  (NKT) and 
that the conventional T cells (CD4 T) differ functionally from conventional T cells in other 
organs (110). However, the difference in T cell function was attributed to the interactions 
between conventional T cells and tolerogenic APC within the context of the liver. In this study, 
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we confirm that the liver is enriched with nonconventional T cells and expand their findings by 
demonstrating that gut bacteria stimulate the development of both conventional and 
nonconventional intra-hepatic T cell subsets.  Our results are consistent with the findings of 
Mazmanian et al. demonstrating that the effect of gut bacteria appears to be limited to CD4+ T 
lymphocytes although CD8+ T and B lymphocytes were not entirely unaffected (108).   
The majority of intra-hepatic nonconventional T cells are NKT cells with NK-like 
cytotoxic activities (58, 89). The role of gut bacteria on NKT cell development is not entirely 
clear (106). Park et al. examined NKT cell development in C57BL/6 mice and found that NKT 
cells in the spleen, liver, and bone barrow develop in the presence or absence of a microbial 
environment (82). Based on the findings of their small sample size (n=2-4), they concluded that 
endogenous glycolipids were sufficient for the development of NKT cells in the aforementioned 
organs (82). The exact identities of endogenous or exogenous glycolipids that promote NKT cell 
development have been difficult to elucidate. Nonetheless, the unifying structural feature of 
microbial CD1d restricted NKT cell antigens seems to be a hexose sugar in an α-anomeric 
linkage with a glycosphingolipid or diacylglycerol and whereas endogenous self lipids include 
phospholipids, lysophospholipids, and sphingomyelin (116).  
Our findings support the concept that gut bacteria as a source of microbial glycolipids are 
not the single most important factor for intra-hepatic NKT cell development. However, our 
results clearly demonstrate that gut bacteria contribute to NKT cell expansion in the liver and are 
in agreement with the NKT cell study performed by Wei et al., which showed decreased iNKT 
cell numbers in the livers of both Swiss Webster and C57BL/6 germ free mice (135). Moreover, 
we show that hepatic expression of adhesion molecules CD44 and ICAM1 (required for 
lymphocyte recruitment to the liver) is regulated to a large degree by exposure to gut-derived 
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MAMPs. Collectively, our data and previous reports indicate that intra-hepatic T cell 
development results from combination of factor including genetic traits, antigenic 
exposure/memory, endogenous self-antigen stimulation, and exogenous stimulation provided by 
residential microbes.   
Identification of the factors that influence intra-hepatic NKT cell developments is critical 
given that NKT cells coordinate effector and regulatory immune responses, combat microbial 
infection, and incite chronic inflammatory diseases (99, 135, 136). NKT cells induce hepatic 
injury following production of copious amounts of immune-regulatory cytokines diseases such 
as alcoholic hepatitis, primary biliary cirrhosis, and autoimmune hepatitis (85, 89). We have 
examined NKT cell mediated damage in the mouse model of autoimmune hepatitis following 
NKT cell activation by α-galactosylceramide. We found that the damage incited by NKT cells is 
severely reduced in GF mice treated with α-galactosylceramide and can be attributed to lower 
NKT cell frequency. Regulation of conventional and nonconventional T cell responses is vital 
for protection from infectious diseases, but also for prevention of autoimmune and 
immunopathologic disorders (106). 
7.3 GUT BACTERIA AND METABOLIC PROFILE 
The gut microbiota aid the host in vitamin uptake and energy extraction with the immense 
number of metabolizing genes they possess and their host’s lack. While, their nutrient extraction 
capabilities are primarily for their own benefit, they increase the available energy available from 
the mammalian diet. Despite their fastidious nature in culture, they can extract energy from high 
fat, high fiber, and low calorie diets in the gut. Because of their resourceful nature, gut 
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microbiota represent an important parameter modulating the amount of energy absorbed from the 
diet, fat deposition, and susceptibility to metabolic disease in addition to genetics, diet, and 
exercise (6).   
 Our data has shown that the gut bacteria influence overall body mass and fat pad size in 
adult mice. In addition, the whole-liver microarray highlights that nearly all hepatic metabolic 
pathways are influenced by the presence of gut bacteria. The influence of gut bacteria is both 
direct and indirect. Gut bacteria directly modulate the liver gene expression profile via MAMP-
PRR interactions. By fermenting indigestible carbohydrates and producing acetate, propionate, 
and butyrate, which can be directly used by various host cells, gut bacteria also indirectly alter 
the metabolic gene expression profile of the liver. It is possible that gut bacteria influence 
metabolic processes in adipose tissue and skeletal muscle including fat mobilization, lipolysis, 
and protein turnover, but this has yet to be investigated. 
 Microbiota dysbiosis (compositional shift) is a major contributing factor for the 
development of obesity (22). In fact, a lean person can be distinguished from an obese individual 
solely on the fermentation profile of their gut microbiota (10). Members of the Firmicutes 
division are better at salvaging energy than those of Bacteroidetes and overrepresentation by 
members of Firmicutes in the microbiota undoubtedly leads to weight gain (12). Therefore, 
obesity studies in rodents should address gut microbial diversity as a contributing factor. 
Furthermore, fecal transplants have been (sparingly) used to treat C. difficile pseudo-
membranous colitis in individuals refractory to antibiotic therapy (137). Likewise, fecal 
transplant might be a viable option to “reset” the microbial community in morbidly obese 
patients in concert with diet and exercise. The role of gut bacteria in development of metabolic 
syndrome and obesity has been an area of recent interest.  
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Obesity and accumulation of fat in the liver as seen in NAFLD and NASH are associated 
with an inflammatory phenotype. In that regard, the microarray provided some insight into the 
immune-related gene changes that could have resulted from changes in the metabolic profile 
attributed to the presence of absence of the gut microbiota to ferment dietary substances or direct 
affects of gut-derived MAMPs on liver cell subsets directly. Either way, the microbiota stimulate 
liver cells, presumably hepatocytes, to express genes associated with innate immunity including 
complement and acute phase proteins.  
We are not the first group to stumble upon the finding that the systemic innate immune 
response is diminished in absence of the gut microbiota. Rouzic et al. previously demonstrated 
that complement proteins are synthesized at a much lower level in prenatal mice (lacking 
microbiota), which is consistent with our results (56). Moreover, the ability of CL but not GF KC 
to augment hepatocyte protein synthesis in vitro corroborates our findings as well (52). These 
data provide more insight into why neonates are more vulnerable to infection.  
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8.0  FUTURE DIRECTIONS 
We primarily focused on bacterial density in liver immune cell population development. 
However both bacterial density and diversity influence host health and disease. Further, the 
inconsistencies in bacterial density between mice can be easily rectified by standardizing 
experimental conditions using a cut-off value of bacterial density to categorize mice as “fully 
colonized” thereby optimizing homogeneity within an experimental group. However, the 
composition of the microbiota of mice may never be fully comprehended. It is important to 
investigate the minimum and maximum numbers of bacterial species required to accomplish 
metabolic function and appropriate immune-stimulation. Differences between mice colonized by 
ASF and possessing many more species have been reported suggesting that eight species are 
enough for mice to reach a specific stage of development but not to reach their full potential.  I 
would propose to classify the murine microbiota species similar to the way that humans have 
been grouped into enterotypes to standardize mouse experiments, especially those planned to 
answer metabolic and immunological questions. Fore example, the BL6 enterotype(s) may or 
may not differ from Swiss Webster enterotype(s) considering that human identical twins have the 
most closely related gut microbiota but still possess diversity variation. Fundamentally, 
answering the questions of bacterial diversity between mice and how closely murine microbiota 
resemble human microbiota would make results from such experiments much more translatable.  
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The potential to perform experiments characterizing bacterial diversity in the murine gut 
exists, but the holdup is primarily financial. If I had all the money in the world and unlimited 
resources, I would perform 454-pyrosequencing on stool from dozens of mice from different 
animal facilities, academic institutions, and commercial vendors using mice from different 
backgrounds given the affect of genetics on bacterial diversity. While preliminary less expensive 
studies like DGGE provide some insight about bacterial diversity between murine individuals, 
our knowledge is incomplete and identifying the species present or absent will give us the 
scientific tools necessary to determine which bacteria are really important. Studies performed 
using individual bacteria overstate the importance of that individual strain. For example, what is 
so spectacular about B. thetaiotamicron other than its ubiquitous nature? It is conceivably 
possible that there is nothing spectacular about this individual bacterium other than the fact that 
it serves as a reservoir for MAMPs. Alternatively, this well-studied gut colonizer could possess a 
unique combination of MAMPs that other colonizers lack enabling it to specifically influence 
different aspects of the immune system in a combinatorial manner. Without full characterization 
of murine microbiota diversity, scientists will continue to make gross overstatements of the 
influence of individual strains of bacteria on host health and development.  
Hundreds to thousands of species colonize the gut. It would be inconceivable to perform 
mono-association studies for each one in order to determine their contribution to liver and 
systemic immunity. Moreover, it would be grossly inappropriate to do so because such 
experimentally contrived mono-association situations are nonexistent in nature and therefore the 
results of such experiments would be essentially useless when trying to discern the significance 
of the individual results when combinatorial studies would be more translational. The problem 
with conventional (combinations of gut bacteria) versus germfree (no gut bacteria) models is that 
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conventional mice have too much going on to figure out which species or classes of species are 
important, dispensable, or redundant. Identifying the bacterial MAMPs, which translocate into 
circulation, in my opinion, was a great advance in this respect. In accordance, the immense gut 
bacterial diversity can be simplified by group classification based on the individual and groups of 
MAMPs they produce. More and more evidence supports that the host immune system sees 
bacteria for their parts and not as whole organisms based on the specialization of PRR and 
detection equipment within particular cellular compartments. In effort not to oversimplify, even 
members of the same bacterial species secrete different forms MAMPs based on selection 
pressures and horizontal gene transfer increasing survival fitness. Even in the aforementioned 
scenarios, FLA is FLA, LPS is LPS, and PDG is PDG because, by definition, MAMPs are 
conserved microbial structures. Now to say all FLA monomers are created equal would be 
unfair, but it is unclear how baseline FLA stimulates the immune system or if different isoforms 
are ‘interpreted’ differently by the host. To date, no specific soluble PRR have been identified to 
bind to FLA unlike LBP for LPS and PGBP for PDG, which holds much significance.  
Rolli et al. demonstrated that minute amounts of FLA could alter cardiomyocyte 
contractility (42). The liver makes most of the proteins found in the blood, but the heart pumps 
the blood around perfusing all organs in the body. The baseline influences of FLA on heart 
contractility and ejection fraction are of great interest. Further, even the kidneys express TLR-5 
and could potentially be influenced by FLA at baseline. The kidneys would be exposed to 
circulating FLA particularly because of their function in blood filtration and fluid homeostasis, 
therefore it would be interesting to determine if FLA influences baseline GFR. Unlike mono-
association experiments with flagellated bacteria (i.e. Salmonella spp.), the proposed 
experiments could be easily performed using axenic animals on elemental diet (no FLA 
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exposure), conventional animals, and axenic animals injected with physiological concentrations 
of FLA systemically. Identifying different stimulatory capacities of various isoforms of FLA 
could be accomplished with this setup as well. 
Microarrays provide a wealth of information that can be a double-edged sword. The 
whole liver is quite heterogeneous although hepatocytes dominate cell number and tissue 
volume. The advantage of performing whole liver gene array is that it provides a picture of the 
forest so to speak, but the drawback is the view of the individual trees is pretty blurry. In other 
words, the gene content of hepatocytes significantly drowned out the gene content of cells found 
at lower frequency. While physiologically, having a 5-10% change in lymphocyte composition 
may mean the difference between mild and severe hepatitis, the gene array was unable to discern 
these differences among germ free and conventional mice based on gene content alone. It would 
be very informative to be able to make predictions of cellular compositional changes in the liver 
based on established high throughput genomic studies. However given the assay limitations, it is 
not possible at this time to make such predictions. To counter the assay limitations, 
deconvolution of the whole liver gene array could be accomplished by performing multiple gene 
arrays on isolated hepatic cellular components and then determining their contribution to the 
total gene pool of the liver. The downside of performing arrays on cell types from heterogeneous 
tissue is not being able to successfully isolate each individual cell type with no contamination by 
other cell types. Nonetheless, deconvolution is worth performing if the resulting information 
would yield further insight into what cell types are collectively influenced by gut-derived 
MAMPs in the liver. It would also provide functional information as to how the expression of 
genes in cell subsets changes in response to constitutive exposure to MAMPs. Although, we 
found many gene changes in response to bacterial colonization including the differential 
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regulation of CD44, some major physiological differences were not elucidated by the gene array 
(i.e. differentially regulated ICAM). Therefore deconvolution will only augment our knowledge.  
We have shown that many leukocyte subsets are indeed recruited to the liver in a MAMP 
dependent manner, however the signaling between non-parenchymal and parenchymal cells and 
their contribution to the recruitment of each cell type adds another layer of complexity. If I were 
to go back (or go forward) investigating Kupffer Cell development, I would utilize the 
‘MacGreen’ mouse model. These mice have a GFP reporter associated with the csf-1 receptor 
specific to monocytes and macrophages thereby making monocytes/macrophages green and 
easily to identify as well as sort.  
Whether or not NKT cell recruitment to the liver is influenced by KC should be more 
thoroughly investigated. One group reported that KC are not required for NKT cell development 
in the liver based on the finding that NKT cell frequency was not altered following KC depletion 
(88). However, I disagree with this interpretation primarily because the establishment of hepatic 
NKT cells may require KC help while maintenance of hepatic NKT cells does not. Moreover, 
because KC express CD1d (in addition to parenchymal and nonparenchymal cells), significant 
KC deficiency as we observed in GF and AVMN mice might alter hepatic NKT cell 
development. The expression of CD1d on hepatic KC should be assessed individually from total 
liver CD1d. In addition, the exact ligands of CD1d recognized by NKT cells have not been well 
described. Methods to detect microbial glycolipid translocation into systemic circulation will 
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